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SYNTHESIS OF THE PENTACYCLIC CARBON FRAMWORK OF THE PF1270 




The PF1270 family of natural products contains novel indole alkaloids that 
display interesting biological activity; the synthesis of these natural products and their 
analogs could lead to the discovery of novel therapeutics. Discussed herein is the 
synthesis of the complete pentacyclic carbon framework of the PF1270s, accomplished 
through a key intermolecular Diels-Alder reaction. Other highlights of the synthesis 
include an acid catalyzed opening lactim ether at a late stage, and a particularly difficult 
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1.1 PF1270 Family of Natural Products 
 
 
Figure 1: Structures of PF1270 A, B, and C. 
 
Histamine is a biogenic amine that has a number of physiological functions and is 
found in several types of mammalian tissue. In 1983, Arrang et al. identified histamine 
receptors (H3Rs) in the brain and peripheral tissue.1 It was later determined that H3Rs 
in the brain act as autoreceptors, controlling the synthesis and release of histamine, and 
as heteroreceptors, controlling the release of the neurotransmitters serotonin, 
noradrenalin and dopamine.2,3,4 Developing a novel synthesis of selective H3R inhibitors 
and their analogs could lead to the development of therapeutic agents for diabetes, 
obesity, cognitive disorders, depression, epilepsy and sleeping disorders. Three H3R 
inhibitors, PF1270 A, B, and C (Figure 1), were isolated from the broth of a Penicillium 
waksmanii strain, found in a soil sample from Shimane Prefecture, Japan in 2007 by 
Kushida et al.  PF1270 A, B, and C have EC50 values of 0.12, 0.15 and 0.20 µM, 
respectively.5 To date there is no record of any biosynthetic studies and as a result little 









PF1270 A (1) R= CH2CH2CH3
PF1270 B (2) R= CH2CH3 





partial synthesis has been reported. Herein we will discuss the isolation, structural 
characterization and biological activity of the PF1270 family of natural products.  
1.1.1 Isolation  
 Three novel compounds, PF1270 A (1), B (2) and C (3), were isolated and 
characterized by Kushida et al. in 2007 from fungal strain PF1270. The PF1270 strain 
was isolated from a soil sample collected in Shimane Prefecture, Japan and was 
identified to be Penicillium waksmanii by morphological characteristics.5 
Fifteen 100 mL Erlenmeyer flasks which each contained a solution of seed 
medium was sterilized and then used.  The medium consisted of glucose (1.0%), 
soluble starch (2.0%), yeast extract (0.3%), polypeptone (0.5%), soybean meal (0.2%), 
wheat germ (0.6%), and CaCO3 (0.2%) in deionized water. The aqueous solution was 
adjusted to pH 7.0 by addition of NaOH. After sterilization a slant culture of the PF1270 
strain was used to inoculate the fifteen Erlenmeyer flasks. These flasks were then 
incubated at 25°C for 72 hours with shaking at 220 rpm. After the allotted time period, 
3.0 mL of the seed culture was transferred to 500 mL Erlenmeyer flasks (100) which 
contained soybean meal (2.5%) and 100 grams of rice that was soaked in water. Each 
flask was stirred once and then kept static at 25°C for an additional 14 days. Once 
finished, the resulting 10 kg portion was then extracted with 20 liters of aqueous 
acetone (67%). The filtrate was concentrated to remove the acetone and then the pH 
raised to 7.0 with 1N NaOH. The aqueous solution was then run on a DIAON HP-20 
column. The column was rinsed with 3 liters of water, 3 liters aqueous acetone, and 
then 3 liters acetone sequentially. To the resulting acetone eluent was added an 
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additional 3 liters of water and the resulting solution was then concentrated under 
reduced pressure. Finally, the resulting aqueous solution was basified to a pH of 9 with 
1N NaOH. The aqueous was then extracted with an equal amount of ethyl acetate and 
the organic phase was concentrated under reduced pressure to afford 3.7 grams of 
crude extract. This extract was purified further by silica gel column chromatography. 
Three different columns were run on the crude extract. The first two were eluted with 
hexanes and EtOAc and the final column was eluted with chloroform and methanol. The 
fractions that contained PF1270 A, B and C were then purified using both preparative 
TLC and preparative HPLC. After purification 70.2 mg of A (1), 17.0 mg of B (2) and 6.0 
mg of C (3)  were isolated.5 
1.1.2 Structural Characterization  
Kushida and coworkers used standard spectroscopic analysis and X-ray 
crystallographic data to establish the relative stereochemistry and to elucidate the 
structure of the PF1270s. PF1270 A (1) was characterized by 1H-NMR, 13C-NMR, 1H-
COSY, HSQC, and HMBC. The molecular formula was established as C32H43N3O6 by 
HR-FAB-MS. Also, the relative configuration was established by X-ray crystallographic 
analysis. PF1270 B (2) and C (3) were characterized by 1H-NMR, and 13C-NMR. The 
molecular formulas were established as C31H41N3O6 and C30H39N3O6 respectively by 
HR-FAB-MS. These three natural products possess the same pentacyclic spirooxidole 
framework, and each posses the unique epoxycarbonyl side chain. The only difference 
in the structure is located on the acyl side chain of the pipecolic acid moiety. A (1) 
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possess a propyl group, B (2) possesses a ethyl group and C (3) possesses a methyl 
group.5 
1.1.3 Biological Activity 
In addition to their interesting molecular framework, the PF1270 natural products 
possess interesting biological activity. This family of natural products does not exhibit 
any antimicrobial activities. All three natural products displayed high affinity for both rat 
and human H3Rs. Like naturally occurring histamine, most H3R ligands possess an 
imidazole ring. This correlation to structure activity relationship is present in both agonist 
and antagonist ligands. Therefore, it is surprising that 1, 2 and 3 are all H3R agonists. 
As shown in Table 1, the Ki values for rat H3R were 0.058, 0.17, and 0.19 µM, 
respectively. The Ki values for human H3R were 0.047, 0.12, and 0.22 µM, respectively. 
All of these compounds acted as potent agonists with EC50 values of 0.12, 0.15 and 
0.20 µM, respectively.5 
Table 1:  Binding affinity (Ki) and potency (EC50) of 1, 2, and 3. 
Compound Rat H3R Ki (µM) Human H3R Ki (µM) Human H3R EC50 (µM) 
1 0.058 0.047 0.12 
2 0.17 0.12 0.15 
3 0.19 0.22 0.20 
 
1.2 Citrinadins  
Citrinadin A (4) and B (5) bear a striking structural resemblance to the PF1270 
family. In 2004, Kobayashi and coworkers isolated citrinadin A (4) from Penicillium 
citrinum, which was cultured from marine red alga Actinotrichia fragilis.6 Then in 2005, 
Kobayashi and coworkers isolated citrinadin B (5) in a similar fashion.7 It should be 
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noted that after the synthesis of citrinadin B by Wood et al.8 and the synthesis of 
citrinadin A by Martin et al.9 the original stereochemical structure was revised. The 
revised stereochemical configuration now aligns with the PF1270s and is shown in 
Figure 2.  
  
Figure 2: Structures of citrinadin A (4) and citrinadin B (5). 
Noticeably, the citrinadins contain the same pentacyclic spriooxindole core and 
the same epoxycarbonyl side chain as the PF1270s. The citrinadins also possess 
noteworthy biological activity. Both 4 and 5 demonstrated activity against epidermoid 
carcinoma KB cells (IC50 10 µg/mL), and against murine leukemia L1210 cells (IC50 6.2 
µg/mL and 10 µg/mL respectively).6,7 Although structurally similar, 1-3 have not been 
tested for analogous cytotoxic activity. Which may be due to the fact that only way to 
access these natural products is by isolation because no total synthesis has been 
reported. Natural product isolation is notoriously difficult and can only provide small 
quantities of 1-3 for biological testing.    
1.3 Other Structurally Related Natural Products  
 Many other natural products containing the spirooxindole moiety have been 








citrinadin A (4) R= 






paraherquamides13-17, the notoamides18-20 and the marcfortines21-23, which have been 
isolated from various Penicillium and Aspergillus fungi. (Figure 3) These natural 
metabolites encompass a broad range of bioactivities including insecticidal, antitumor, 
anthelmintic, antiparasitic and antibacterial properties. While the biosynthesis of the 
PF1270s remains a mystery, extensive research has been done on the synthesis and 
biosynthesis of these natural products.24-25 Furthermore, copious research has been 
done by Williams et al. to elucidate the biosynthesis of the paraherquamides.26-28 The 
complex amino acid structure found in these natural products is comprised of tryptophan 
unit, a cyclic amino acid unit, and one or two isoprene units. 
 
Figure 3: Structures of members of the brevianamide, paraherquamide, notoamide and 















































 To date, no total synthesis of the PF1270s has been reported. Both the PF1270s 
and citrinadins have been the focus of interest in the synthetic community due to their 
interesting molecular scaffold, as well as their interesting biological activities. Since the 
isolation of the PF1270s and citrinadins, there have been a number of different synthetic 
studies towards the pentacyclic core present in both of these natural products. In 
addition, the first total synthesis of both citrinadin A and citrinadin B were recently 
reported. Below is a discussion on the relevant syntheses that have been reported to 
date.  
2.2 Martin Group Spirooxindole Synthesis 
 Martin et al.28 envisioned the spirooxindole moiety arising from an 
enantioselective oxidative rearrangement, initially reporting the synthesis prior to 
reassignment of the citrinadin A stereochemistry.29 They hypothesized that citrinadin A 
could arise from a Negishi coupling of triflate 11 with pipecolinic 12, in which they 
envisioned that 11 could arise from a key enantioselective oxidation rearrangement of 
indole 13. The enantioselectivity of the spirooxindole was proposed to arise from either 
epoxidation of indole 13 with a chiral dioxirane, or through facial selectivity that would 




Scheme 1: Martinʼs retrosynthetic approach to citrinadin A (10). 
 To test this hypothesis 15 and 16 were synthesized in five steps from diketone 
14. Intermediate 16 was used to test the asymmetric epoxidation approach, while 15 
was used to test the chiral auxiliary approach. Both of these intermediates were then 
used to screen conditions for the enantioselective oxidative rearrangement.  
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First, intermediate 16 was submitted to standard Shi asymmetric epoxidation 
conditions.30-32 Initial treatment of 16 with D-epoxone was low yielding and showed no 
asymmetric induction; however, treatment of 16 with related N-aryloxazolidinone,33 
followed by deprotection of the N-acetyl, gave 19 in 77% yield over both steps and 74% 
ee. (Scheme 3) 
 
Scheme 3: Enantioselective oxidative rearrangement of 16. 
A concurrent approach utilizing a chiral auxiliary was also investigated. To start, 
intermediate 15 was treated with DMDO in acetone. Upon purification of epoxide 20 
using column chromatography, small amounts of spirooxindole 21 were observed.  The 
authors used this to their advantage, and upon stirring epoxide 20 over silica using DCM 
as the solvent, they observed full conversion to 21. The authors confirmed that absolute 
stereochemistry of the spirocenter matched 10 by X-ray crystallography. Finally, 21 was 































Scheme 4: Diastereoselective oxidation of 15. 
Martin and co-workers were the first to devise a synthesis for the citrinadin family 
of natural products. They achieved the first reported enantioselective oxidative 
rearrangement of an indole intermediate to a spirooxindole. Furthermore, they were the 
first group to develop and report the synthesis of the spirocenter present in citrinadin A. 
2.3 Deiters Group Synthesis of the Tricyclic Core 
 In 2010, Deiters and co-workers34 developed a two-step [2 + 2 + 2] 
cyclotrimerization-substitution reaction that was used to synthesize the pentacyclic core 
of the citrinadins and the PF1270s. First, using commercially available starting 
materials, they screened reaction conditions. They started by submitting diyenes 23 and 
24 to cyclotrimerization conditions. With the use of CpCo(CO)2 catalyst in toluene under 
microwave irradiation alcohol 25 was synthesized, and immediately converted to the 
desired mesylate 26. To accomplish this transformation with out the need of purification, 
































converted to 27 by treatment with NaBH4 in MeOH and H2O in excellent yields. (Scheme 
5) 
 
Scheme 5: Two-step [ 2 + 2 + 2] cyclotrimerization-substitution reaction. Followed by 
reduction to form tricyclic 27. 
Deiters and co-workers then synthesized the pentacyclic core of the citrinadins 
and the PF1270s using the optimized conditions. In three steps and 39% yield 29 was 
synthesized from known 28. With desired 29 in-hand, they effected the 
cyclotrimerization reaction by treatment with CpCo(CO)2 catalyst under microwave 
conditions in the presence of 24. While most of the TMS moiety was cleaved to form 30 
under the initial microwave irradiation, a small amount of the silylated intermediate 
remained. In order to remove the remaining TMS moiety, the reaction was treated with 
KF under microwave irradiation. Substrate 30 was then mesylated and eliminated using 
the previously described conditions to form pyridinium compound 31. Reduction of 31 
with NaBH4 provided the desired pentacyclic core (32) in good yields.  Deiters et al. 
were able to construct the complex pentacyclic core (32) in a 30% yield from the diyne 




















Scheme 6: Synthesis of the racemic pentacyclic core 32. 
2.4 Sorensen Group Synthesis of the Citrinadin Core 
In 2011, Sorensen et al.35 synthesized a highly functionalized pentacyclic core of 
the citrinadins. The synthesis started with a mixed Claisen acylation of tryptophan 33 
with pipecolic ester 34 to afford substrate 35 with high yields and good 
diastereoselectivity. The β-keto ester 35 was then treated with SOCl2 to remove the Boc 
group. The resulting residue was then treated with excess POCl3 and heated at reflux.  
The reaction mixture was  concentrated, treated with neat TFA, and stirred for two days 
to afford the desired lactam 36. Substrate 36 was then treated with iso-
propenylmagnesium bromide to selectively install the central isoprene. The favorable 
diastereoselectivity (10:1) was induced by lower reaction temperatures and afforded 37. 
Indole 37 was subsequently deprotected using Mg powder. The free indole then 
underwent cycloisomerization in the presence of Hg(O2CCF3)2 followed by reductive 
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Scheme 7: Sorensen synthesis of 38. 
Sorensenʼs previous unpublished studies showed problems with protecting group 
liability during the oxidative rearrangement to the spirooxindole. To alleviate any 
possible problems, they planned a protecting group swap prior to the oxidative 
rearrangement. The methyl carbamate 38 was first removed with excess BBr3S(CH3)2, 
furnishing 39 in excellent yield.  The resulting lactam was subsequently reduced in the 
presence of Red-Al, and the primary amine was then converted to azide 40 by treatment 
with TfN3. Prior to the oxidative rearrangement, the indole nitrogen was Boc protected 
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conditions previously described in their group, as well as work by Petrini and co-
workers,36 was used to convert 41 to 42. First, 41 was treated with TFA to protonate the 
tertiary amine, which was followed by the addition of an excess amount of exogenously 
generated trifluoroperacetic acid. Finally, the reaction was quenched with dimethyl 
sulfide to afford 42 in a 33% yield. The Sorensen group was then first to synthesize the 
highly functionalized pentacyclic core of the citrinadins. (Scheme 8) 
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2.5 Martin Group Total Synthesis of (-)-citrinadin A 
 Recently Martin et al.37 reported the first total synthesis of citrinadin A. Their 
synthesis highlights an asymmetric vinylogous Mannich reaction and a substrate 
controlled oxidative rearrangement. In addition, the synthesis was completed in 20 steps 
from commercially available starting materials and resulted in the revision of the 
citrinadin A structure. 
 Their synthesis commenced from commercially available dione 14, the same 
dione they used in their previously described synthesis of the spirooxindole.28 Dione 14 
was converted to amino alcohol 43 in 12 steps, which included an asymmetric 
vinylogous Mannich reaction. With the amino alcohol in-hand, they next turned their 
attention to constructing the pentacyclic core. First, 43 was heated in the presence of 
acid and o-bromophenyl hydrazine hydrochloride to afford indole 44 in excellent yields. 
Normal reduction conditions of the amide, using only alane, provided moderate yields of 
the desired product 45; however, treatment with alane followed by NaCNBH3 gave 
excellent yields.38,39 They initially screened a number of different conditions for the 
formation of the spirooxindole moiety, yet all of their initial attempts failed. Formation of 
the spirooxindole was finally achieved by using conditions previously described by 
Williams and co-workers.40-42 First, indole 45 was treated with PPTS to protect the 
amino groups from oxidation via protonation, and then treated with Davisʼ oxaziridine to 
form epoxide 46. Epoxide 46 was then treated with AcOH to furnish spirooxindole 47 in 




Scheme 9: Martinʼs synthesis of spirooxindole 47. 
In order to install the requisite side chains, 47 was first treated with a 
Sonogashira coupling with 3-methylbut-1-yne to furnish alkyne 48, which was then 
acylated with N,N-dimethyl-L-valine, EDCI and DMAP to provide 49. Enone 50 was 
synthesized from a gold catalyzed oxidation of 49.43 Finally, the epoxide was installed 
using a diastereoselective epoxidation method that was established by Enders et al.44 
Treatment of 50 under these conditions furnished 4 and 51 as a separable (5:1) mixture. 
(Scheme 10) 
The CD spectrum of 4 was identical to that reported for citrinadin A whereas, the 
CD spectrum of 51 was not a match. Furthermore, 1H and 13C data of 4 also matched 
the reported data provided by Kobayashi. Thus they strongly suggest that the correct 
structure for citrinadin A is 4 and not 10.  
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Scheme 10: Martinʼs total synthesis of citrinadin A. 
2.6 Wood Group Total Synthesis of (+)-citrinadin B 
 Concurrent to Martinʼs synthesis of citrinadin A, the Wood group45 published the 
first reported synthesis of citrinadin B. The Wood group utilized a key stereoselective 
intermolecular nitrone cycloaddition as the key step in their synthesis. After the 
completion of their synthesis, they revised the stereochemistry of citrinadin B.  
Wood and co-workers started with commercially available dibromo aniline 52, 
which was converted to 53 in 11 steps and 17% yield. Intermediate 53 was then used in 
the critical [3 + 2] cycloaddition. While a variety of diastereo- and regioisometric 
products were anticipated to result from this reaction, they were pleasantly surprised to 















































































studies to determine the stereochemical configuration, they determined that the two 
products differed at the spirooxindole center. Unfortunately, the minor product contained 
the same stereochemical configuration found in the natural product. (Scheme 11) 
 
Scheme 11: Synthesis of cycloaddition products 54 and 55.  
 With the correct enone in-hand, a Corey-Chaykovsky epoxidation of 54 provided 
spiroepoxide 56 as a single diastereomer;46 however, all attempts to promote 
intermolecular opening of 56 failed. Thus, they treated 56 to in situ generated TMSI and 
were able isolate ammonium salt 58 through proposed intermediate 57. Diol 59 was 
formed via a Zn mediated N-O bond cleavage of 58. Substrate 59 was then treated with 



































Scheme 12: Formation of the epoxide 60. 
With the desired pentacyclic core intact, all that remained was to attach the 
requisite side chain and install the methylamine functionality. Conditions used for the 
instillation of the desired epoxiketone side chain mirrored those of Martin.37 Epoxide 60 
was coupled to 3-methyl-1-butyne under Sonogashira conditions to provide alkyne 61, 
which was subsequently benzyl deprotected and treated with MgCl2/NaN3 to form azide 
62. Using gold mediated oxidation conditions, azide 62 was converted to azido alcohol 
63,43 which was subsequently submitted to epoxidation conditions developed by 
Enders,44 Boc protection then afforded 64 and 65 in a mixture (1:7) of separable 
isomers. It should be noted that the initial epoxidation step led to a mixture of 



























































methylamines using the same reaction sequence. First, the azide was reduced to the 
amine via treatment with Pd/C, and the resulting free amine was monomethylated using 
methyl Meerwein salt. Finally, the indole was deprotected by treatment with Mg(CIO4)2 
to afford substrates 66 and 5. (Scheme 13) 
 
Scheme 13: Synthesis of citrinadin B (5). 
 After comparing the spectral data for both 66 and 5 to the spectral data obtained 
for the natural product, the structure of citrinadin B was reassigned. While Kobayashi 
originally proposed the structure of citrinadin B as 66, Wood et al. determined that the 
correct structure is actually 5. This aligns with reassignment of citrinadin A proposed by 
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2.7 Sarpong Group synthesis of the citrinadin core 
In 2013 Sarpong et al.47 reported a synthesis of the citrinadin core. Their 
synthesis shares some synthetic strategies found in both the Martin and Wood 
synthesis.  
Sarpong starts with the same commercially available dione 14 that Martin used, 
which was converted to ketone 67 in five steps and 27% yield. Fisher indole conditions48 
were utilized to first form dihydrocarbazole 68, followed by formation of indole 69. 
Treatment of indole 69 with DIBAL reduced the ethylester to the corresponding alcohol. 
Subsequent epoxidation furnished 70, which was treated with MgCl2 and then NaI to 
afford substrate 71. Diastereoselective hydrogenation of pyridine 71 afforded pentacycle 
72 in excellent yields. The structure of 72 was confirmed by X-ray crystallography. 
Indole 72 was then treated with oxone in acetone to afford spirooxindole 73. This 
oxidation also proceeded with high levels of diastereoselectivity, which they attributed to 
both the oxidation at the more accessible convex face and directed oxidation for the 
primary alcohol. Subsequent Boc deprotection, followed by amide reduction provided 
intermediate 74. Unfortunately, despite screening a number of different conditions they 




Scheme 14: Synthesis of diol 74. 
 After attempting numerous conditions, they decided upon an alternative strategy 
for the synthesis of the desired carbon skeleton. Using a strategy similar to what Wood 
used in his synthesis of citrinadin B,45 epoxide 70 was treated with Tf2O and 2,6-DTBP 
providing pyridinium salt 76. Without purification, salt 76 was treated with NaI in 
refluxing MeCN to afford pyridone 77. Next, catalytic hydrogenation afforded 78 with 
































































1. !, MeCN, MW
2. AlH3, -78 






















excellent diastereoselectivity. Finally, indole 78 was oxidized to spirooxindole 79 using 
the previously described conditions, and the structure was confirmed using X-ray 
analysis. (Scheme 15) 
 
Scheme 15: Alternative route to pentacyclic 79. 
While the relative stereochemistry at C-3 and C-16 are correct, Sarpong and 
coworkers note that the relative stereochemistry at C-18 will require inversion. Ongoing 
studies in their group are addressing both the stereochemical inversion as well as 
nucleophilic opening of the epoxide group. Although work still remains on this project, 























































 While there have been a number of different synthetic strategies reported to 
synthetize the pentacyclic core of the PF1270s, a total synthesis remains to be reported. 
The recent elegant syntheses reported by Martin37 and Wood45 remain the only 
syntheses of the citrinadins, and the need for other convergent and elegant synthetic 








3.1 General Synthetic Strategy 
To date, no total synthesis of the PF1270s has been reported. As previously 
described, the pentacyclic core of the PF1270s and citrinadins has been 
synthesized;34,35,47 there have also been two recently reported total syntheses of the 
citrinadins.37,45 With all of the previous synthetic routes in mind, we designed a 
completely novel synthesis for the construction of the pentacyclic core. Our plan 
centered on previously developed Williams group chemistry in the total synthesis of 
similar spriooxindole alkaloids, such as the paraherquamides39,49 and marcfortines41,50. 
Both of these natural products were synthesized utilizing a key Diels-Alder reaction to 
set the stereochemistry of the bicyclo[2.2.2.]diazaoctane core. Utilizing a similar Diels-
Alder reaction, we hypothesized that we could rapidly access the desired pentacyclic 
core, which could further be elaborated into the exact carbon framework of the 
PF1270s. Furthermore, after successfully synthesizing the pentacyclic core, we planned 
on employing the same synthetic strategy to complete the first reported total synthesis 
of 1. 
3.2 Retrosynthetic Plan 
As such, we proposed a retrosynthetic plan for the synthesis of the pentacyclic 
core starting from reverse prenylated tryptophan 80 and hydroxypipecolic acid derivative 




Scheme 16: First generation retrosynthetic plan. 
We envisioned forming the complete pentacyclic core of PF1270 (82) by 
decarboxylation of 83, which could be synthesized via acid catalyzed cleavage of the 
bridging amide present in 84. A significant precedence for acid catalyzed cleavage of 
the bridging amides can be found in the literature.51 We envisioned forming the bridged 
pentacycle 84 through our previously developed intermolecular Diels-Alder (IMDA) 
reaction. The IMDA reaction would be utilized to set the stereochemistry of the bridging 
amide as the desired anti-diastereomer. In the synthesis of (-)-versicolamide B, our 
group has shown that the IMDA reaction on spirooxindole intermediates provided 
exclusively the anti-diastereomer;52 this synthesis provided experimental support for the 

























































form the sprirooxindole prior to the IMDA reaction. The required azadiene precursor (85) 
could be formed by submitting spirooxindole 86 to Mitsunobu conditions followed by 
treatment of the resulting enamide with base. An oxidative rearrangement of 87 would 
then give rise to the spirooxindole intermediate 86. Precursor 88 could be synthesized 
through a peptide coupling and subsequent deprotection/cyclization to give DKP 87 
(Scheme 16). 
3.2.1 Synthesis of the Pipecolic Acid Derivative 
To start the synthesis of the pentacyclic core, a route to readily synthesize the 
desired pipecolic acid derivative in large quantities was needed. We chose a synthetic 
plan based on work previously described by Knight and co-workers.56 This group 
synthesized the desired pipecolic acid derivative (81) via an enzymatic reduction of 
ketone 89 which was formed through a Dieckmann condensation of diester 90 (Scheme 
17). 
 
Scheme 17: First generation retrosynthesis of pipecolic acid derivative.  
Our synthesis of the diester 90 was achieved via the route shown in Scheme 18.  
A nucleophilic substitution of ethyl bromoacetate (91) with 2-pyrrolidinone (92) in the 
presence of sodium metal provided 93, which was then treated with HCl to afford free 
amine diacid 94. Subsequent Boc protection followed by esterification of 94 afforded 




















mixture of two products (96 and 97) of which, the undesired product 96 was the major 
product. A number of different reaction conditions were screened in an effort to produce 
the desired product in higher yields, however, all the conditions we screened failed. The 
desired product 97 was then submitted to the enzymatic reduction in the presence of 
bakerʼs yeast to produce 98.  On a small scale, after some optimization, the reduction 
proceeded with excellent yields. The subsequent deprotection and conversion to 
desired free amine 99 was completed smoothly.  However, on large scale the bakerʼs 
yeast reduction was low-yielding and proved to be more problematic.  When carried out 
on a large scale the amount of bakerʼs yeast required for the reduction formed a thick 
paste that made extraction extremely difficult. This resulted in only a twenty percent 
recovery of the desired product from the aqueous paste. As this synthetic plan 
contained both a low-yielding Dieckmann condensation and a low-yielding bakerʼs yeast 
reduction, a new route was devised.   
 






















































3.2.2 Second Generation Pipecolic Acid Synthesis 
We believed that we could access the desired pipecolic acid ester 81 by 
esterification of acid 100. (Scheme 19) Desired acid 100 could arise from a reduction of 
commercially available 3-hydroxypicolinic acid 101.  
 
Scheme 19: Second generation retrosynthesis for pipecolic acid derivative. 
Following a literature procedure, catalytic hydrogenation of 101 gave only trace 
amounts of product.57 Increasing both the pressure and the duration of the reaction 
allowed for a substantial product recovery. With our desired acid in-hand, the 
esterification was carried out in the presence of thionyl chloride and EtOH at reflux 
providing 81 in good yield over 2 steps. (Scheme 20) More importantly, this reaction 
sequence was scalable and allowed us to access large amounts of the desired acid. 
With pipecolic acid derivative 81 in-hand, we turned our attention to the synthesis of 
reverse prenylated indole 80. 
 
Scheme 20: Synthesis of the desired pipecolic acid derivative. 
3.2.3 Synthesis of the Tryptophan Derivative 
The synthesis of the reverse prenylated tryptophan precursor 80 is shown below. 





























chlorosuccinimide to provide 103, which was treated with prenyl-9-BBN to provide the 
C-2 reverse prenylated indole 104 in 78% yield. Next, a Mannich reaction afforded 
gramine 105, which was coupled with glycine benzophenone imine to afford tryptophan 
derivative 106 in good yield. Cleavage of the benzophenone imine with aqueous HCl 
afforded free amine 107, which was subsequently Boc-protected to provide 108.  
Finally, ester 108 was saponified with LiOH to provide acid 80. With both the desired 
pipecolic acid and reverse prenylated tryptophan in-hand, we turned our attention to the 
IMDA reaction.  
 
Scheme 21: Synthesis of the reverse prenylated indole derivative. 
3.2.4 Initial IMDA Attempt 
The coupling of pipecolic acid 81 to 80 in the presence of HATU afforded 109 in 




















































the free amine which, upon basic work up, cyclized to diketopiperazine 110 in 92% 
yield. Treatment of 110 with Davisʼ oxaziridine (111) formed the desired spirooxindole 
112 in 74% yield.  
Our group previously showed a one pot cycloaddition of a similar spirooxindole.50 
However, heating 112 in the presence of excess PBu3 and DEAD did not afford the 
expected cycloaddition product 114. Since the one-pot elimination Diels-Alder addition 
failed, we turned to a known two-step procedure58-60. Starting from alcohol 112, a 
Mitsunobu-type elimination afforded enamide 115 in moderate yields. Nevertheless, 
when enamide 115 was treated with KOH/MeOH none of the desired cycloadduct 114 
was detected.  
 



















































































Unfortunately, all attempts to synthesize the cycloadduct from both the R- and S-
oxidole moieties failed. We believe that there is a competing retro-Michael reaction that 
is more facile than the desired IMDA reaction (Scheme 23). This retro-Michael reaction 
was first reported in our group by Dr. Kathleen Halligan in her synthesis of the 
brevianamides,61 and also by Dr. Jennifer Finefield in her synthesis of (-)-
versicoleamide B.62 The undesired side reaction could be easily avoided by forming the 
Diels-Alder adduct prior to the oxidation to the spirooxindole.62 
 
Scheme 23: Probable retro-Michael reaction. 
3.3 Second Retrosynthetic Plan  
Since the desired cycloadduct could not be synthesized as originally planned, an 
alternative route was devised. We envisioned the complete pentacyclic core of the 
PF1270 family coming from a late stage decarboxylation of acid 118 and subsequent 
oxidation to the spirooxindole. Acid 118 could arise from the same proposed acid 
catalyzed cleavage of the bridging amide 120.  Amide 120 would come from the IMDA 
reaction of azadiene 121.  The azadiene precursor 122 could be formed by submitting 
DKP 110 to Mitsunobu conditions, followed by treatment of the resulting enamide with 
base. Finally, DKP 110 could arise from the same previously described coupling and 































Scheme 24: Second generation retrosynthetic analysis. 
3.3.1 Synthesis of the Diels-Alder Product 
As previously described, DKP 110 was formed by first coupling tryptophan 80 
with pipecolic acid 81, followed by deprotection/cyclization. Enamide 122 was formed in 
72% yield by Mitsunobu-type elimination of alcohol 110. Treatment of enamide 122 with 
KOH and MeOH gave cycloadducts 123 and 124 in a 1.5:1 ratio. It is important to note 
that this is a bottleneck of the synthesis as this IMDA reaction provides the desired anti-
adduct as the minor product. However, with a route to the desired cycloadduct in-hand, 




































































Scheme 25: Synthesis of the IDMA cycloadducts 123 and124. 
3.3.2 Opening of the Bridging Amide 
Initially we believed that opening the bridging amide would proceed smoothly, but 
it turned out to be quite challenging. First we attempted to hydrolyze 123 and 124 to the 
corresponding acids (125 and 126) using 6M HCl.63-66 (Scheme 26) At room 
temperature for 24 hours, we only recovered starting material. Next, the reaction was 
















































































Scheme 26: Attempted hydrolysis of bridging amide. 
Next we reduced the tertiary amide hoping that its reduction would change the 
reactivity of the system thereby allowing the bridging amide to be hydrolyzed. Treatment 
of both the syn 123 and anti 124 cycloadducts with DIBAL in toluene provided 
cycloadducts 127 and 128. Nevertheless, treatment of both 127 and 128 with 6M HCl 
failed to afford acids 129 and 130. (Scheme 27) 
 
































































































Under acidic conditions we failed to open the bridging amide; consequently we 
decided to attempt the opening under basic conditions.67-70 Again, treatment of both 123 
and 124 with 1M NaOH at room temperature yielded only starting material, while 
treatment with 1M NaOH at reflux resulted in decomposition. Under basic conditions we 
were still unable to produce acids 125 and 126. (Scheme 27) 
 
Scheme 27: Attempted ring opening under basic conditions. 
Because attempts at hydrolysis under both basic and acid conditions were 
unsuccessful, we hypothesized that increasing the amideʼs reactivity might allow us to 
open the bridging amide.71-74 Therefore, amide 123 was first converted to protected 
amide 131 by treatment with Boc2O and TEA in DCM. Next, we converted amide 123 to 
methyl amide 132 by treatment with NaH and MeI in DMF. However, all attempts to 










































Scheme 28: Attempted opening of the amide to the ester. 
Unfortunately, all of the screened conditions were unsuccessful. The opening of 
the bridging amide proved to be more problematic than we had originally anticipated, 
and we were forced to devise another alternative route.  
3.4 Third Retrosynthetic Plan 
In this new plan, the early stages of the synthesis remained the same and only 
the later stages changed.  Our new plan was based on previous chemistry done in the 
group. In the synthesis of the stephacidin A and notoamide B, we observed the ring 
open conformer during deprotection the lactim ether (Scheme 29).75,59 In these 
examples, only the syn conformer stayed open and the anti-conformer was isolated as 
































































Scheme 29: Previous synthesis of stephacidin A and notoamide B. 
 We believed that after reaction optimization, we would be able to isolate both 
ring open conformers (138). In order to test our theory, we first had to synthesize the 
required lactim ether intermediates. The desired lactim ethers 139 and 140 could come 
from the IMDA reaction of azadiene 141. The azadiene would come form lactim ether 
142, which could in turn arise from a methylation of the previously synthesized enamide 
122. Enamide 122 could come from the same reaction sequence as previously 



































Scheme 30: Third generation retrosynthesis. 
3.4.1 Third Generation Synthesis 
 This synthesis begins as before with a HATU coupling of indole 80 to pipecolic 
acid 81 affording dipeptide 109.  Dipeptide 109 was then treated with TFA to afford the 
free amine which, upon basic workup, provided the cyclized DKP 110. DKP 110 was 
then treated with PBu3 and DEAD to provide enamide 122. Enamide 122 was then 
treated with Meerweinʼs salt to afford lactim ether 142, which was then treated to KOH 
in MeOH to provide the IMDA cycloadducts syn 139 and anti 140. (Scheme 31) With the 
desired substrates in-hand, we turned our attention to conditions for opening of the 






























































Scheme 31: Third generation synthesis. 
3.4.2 Opening of the Bridging Amide 
Mikler and co-workers showed that treatment of nitrogen-containing heterocycles 
143 with CSCl2, CaCO3 in DCM afforded isothiocyanate 144.76,77 Also, Fernandez and 
co-workers utilized identical reaction conditions to convert 145 to isothiocyanate 146.78 
Using the aforementioned conditions, we submitted 139 to CSCl2 and CaCO3 in DCM 
for 5 hours or overnight. Unfortunately, we never observed the desired isothiocyanate 


























































































Scheme 32: Synthesis of isothiocyanates 144, 146 and attempted synthesis of 147. 
Next, we decided to attempt opening the lactim ether using the conditions that 
were previously described in our group. Thus we followed the exact procedures found in 
the synthesis of stephacidin A. 75,59 A mixture of syn 139 and anti 140 cycloadducts was 
cooled to 0 °C in THF and 0.1M HCl was added dropwise. The reaction was then 
allowed to warm to room temperature and was quenched with NaHCO3. Under these 
reaction conditions, we isolated a mixture of both open and closed conformers. Anti 124 
was isolated, unfortunately none of the desired ring open compound was observed. The 
syn isomer was isolated as both the ring open conformer 148 and the bridging amide 















































Scheme 33: First attempt at opening the lactim ether. 
As we knew that this reaction must proceed via the ring open conformer, we 
postulated that we could prevent intramolecular cyclization by trapping the free amine. 
First, we attempted to trap the free amine as the phthalimide protected amine.79 
However, treatment of 140 with HCl in the presence of phthalic anhydride only provided 
124 and we did not observe 149. (Scheme 34)  
 
Scheme 34: Attempted phthalimide protection. 
 Although our initial attempt at trapping the free amine was unsuccessful, we 
decided to try an alternative method to trap the amine.80 Lactim ethers 139 and 140 
were first dissolved in THF and 20 equivalents of Ac2O were added. Then 0.1M HCl was 
added dropwise over five minutes at 0 °C. The reaction was allowed to stir at 4 oC 
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syn 148 and anti 150 open products, but the major products were still the bridging 
amides 123 and 124. (Scheme 35) Every attempt to optimize the reaction was 
unsuccessful. We were never able to exclusively form the desired acetate protected 
amines (148 and 150) without the formation of the undesired side products (123 and 
124). We decided that this reaction sequence would not provide us with enough material 
to complete the  PF1270 synthesis.  
 
Scheme 35: Trapping of the free amine with acetic anhydride. 
Since the ring open conformers remained the minor products of the reaction, we 
turned our attention to the acid catalyzed hydrolysis of the lactim ether. We hoped that 
by further optimizing these reaction conditions, we would be able to isolate the ring open 
conformers as the major products. As previously stated, we needed to disfavor the 
intramolecular cyclization. As quenching with NaHCO3 would only promote the 
cyclization, we decided to quench with a pH 7 buffer instead. Also, we hoped that 
controlling the reaction temperature would allow us to isolate more of the desired 
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 44 
keep the reaction at 0 °C. We submitted 139 and 140 to these reaction conditions and 
were pleasantly surprised. We observed a small amount of the ring open anti adduct 
151. Unfortunately, 151 remained a minor product of the reaction, and the 
intramolecular cyclization product 124 remained the major product of the reaction. 
(Scheme 36) 
 
Scheme 36: Formation of anti 150. 
Next, we hoped to increase the quantity of 148 and 151 by slowing the addition of 
acid. To a mixture of 139 and 140 dissolved in THF was added 0.1M HCl dropwise over 
8 hours, making sure to keep the reaction at 0 °C for the entire addition. Once the 
addition was complete, we placed the reaction in a cold room for another 8 hours. TLC 
analysis showed that starting material was consumed and only two products were 
observed. The reaction was worked up by quenching with pH 7 buffer and extracting 
into ether. Three products were isolated: 148 and 151 as the major products, and 124 















































Scheme 37: Formation of 148 and 151 as major products. 
Bridging amide 124 was not observed prior to workup, but was isolated after 
workup. We believed that during the workup, the reaction was warmed to room 
temperature thereby promoting the intermolecular reaction. In order to test this 
hypothesis, we submitted 140 to the same reaction conditions, but we were careful not 
to allow the aqueous and organic phases to warm to room temperature during workup. 
To our surprise we were able to isolate 151 as the aole product by TLC. It should also 
be noted that the free amine is not stable and in solution it will spontaneously form 124. 
Free amine 151 was so unstable in solution that obtaining an NMR was difficult; 
consequently, the free amine must be taken directly on to the next step. Next we turned 
our attention to amine protection. This step also proved problematic.  
3.5 Late Stage Retrosynthetic Plan  
 After considering many different protecting groups we decided on carbamate 
protection in order to functionalize the carbamate later in the synthesis. We believed 
that we could readily access the desired core (82) via a late stage oxidation to form the 







































153 which at the same time would provide the desired methylamine 152.81 Amide 153 
would come from a decarboxylation of acid 154 which could arise from a two-step 
protection of 138 followed by hydrolysis of methylester 155.  (Scheme 38)  
 
Scheme 38: Late stage retrosynthetic plan. 
3.5.1 Boc Protection of the Free Amine 
Numerous attempts were made to form the desired Boc protected precursor from 
syn 148. However, all attempts resulted in the formation of undesired bridging amide 
123 as the major product. During our initial screening, we started with traditional 
conditions for Boc protection. Boc2O, with TEA in DCM yielded 123 as the major 
product.82 We also tried adding DMAP to the above mentioned reaction conditions and 
saw no change in the ratio of products. Finally, we decided to omit the base completely 










































this reaction was kept at 0 °C the reaction was slow, and no products formed. At room 
temperature for days small amounts of both products were formed. Finally, at reflux, the 
reaction went to completion overnight, albeit with 123 as the major product. (Scheme 
39) 
 
Scheme 39: Attempt to form adduct 156.  
3.6 Late Stage Retrosynthesis, Revised 
Since all attempts to protect the free amine as the carbamate were unsuccessful 
an alternate route was devised. After careful consideration we decided on acetate 
protection. The late stage synthesis remained the same in that we planned on 
accessing the desired core 82 via a reduction of protected amine 153, followed by an 



























































































through a protecting group swap on 157. The protecting group swap would allow for a 
one-pot reduction/methylation. Otherwise, a two step methylation and then deprotection 
of the acetate group would be required prior to the reduction of the amide moiety.  
Substrate 157 could arise from a decarboxylation of acid 158. Acid 158 could arise from 
an acetate protection of 138 followed by hydrolysis of ester 159. (Scheme 40) 
 
Scheme 40: Late stage retrosynthesis revised 
3.6.1 Acetate Protection of the Free Amine 
 The initial reaction screening was done on the syn adduct in an effort preserve 

















































temperature in hopes of slowing the intermolecular reaction. To test if the added base 
would promote the intermolecular reaction, we tried the reaction with the addition of 
base. Amine 148 was dissolved in THF and cooled to -78 °C and Ac2O was added, 
followed by TEA. The reaction was then allowed to warm to -15 °C and stirred overnight. 
As expected, the major product was 123, and 160 was the minor product. After careful 
consideration we decided to omit the base and retry the reaction. We repeated the 
reaction only adding the Ac2O at -20 °C and kept the reaction at -20 °C. The reaction 
was very slow and took days to go to completion at this temperature. Thus the reaction 
was allowed to slowly warm to 0 °C overnight in hopes of speeding up the reaction time. 
Under these conditions, the reaction went to completion and provided us with the 
desired acetate protected amine 160 as the major product.  With the desired product in-





Scheme 40: Acetate protection of the free amine.  
3.6.2 Conversation of the Ester to the Acid 
 With 160 in-hand, we turned our efforts to the synthesis of decarboxylation 
precursor 161. By all accounts, the conversion of ester 160 to the desired acid 161 
looked to be straightforward. (Scheme 41) 
 
Scheme 41: Conversation of ester 160 to desired acid 161. 
This conversion, proved to be quite challenging. (Conditions summarized in Table 2) We 
submitted ester 160 to 1M LiOH in THF for days at room temperature;83,84 these 
Ac2O, TEA
DCM
-78o to 0o C
THF
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 51 
conditions resulted in complete recovery of starting material, so the reaction was 
refluxed for 3 days, leading to decomposition. Next, we tried to effect the same 
conversion by treating 160 with Me3SnOH.85,86 Attempts at different temperatures and 
durations resulted in no reaction. Treatment of the ester with LiCl using microwave 
conditions resulted in a 15% yield of 161;87 due to the low yield of this reaction 
alternative conditions were considered.  
We postulated that all of the above conditions were failing due to the steric 
interactions.  Both the ester and protected amine are on the same face of the 
hydrocarbon framework, causing the steric bulk of the protected amine to block the 
ester from nucleophilic addition. In an effort to test this theory, we used a reagent 
designed for the conversion of sterically hindered methyl esters to acids. This reagent 
was developed by Corey et al., and was utilized in their synthesis of 
salinosporamide.88,89  The desired methyltellurate reagent was synthesized by refluxing 
tellurium powder and (Me3Al)2 in toluene. The resulting 0.8 M solution was then added 
to ester 160 in DCM and stirred at room temperature for 6 hours. When the reaction was 
complete, it was quenched with 1 M HCl and stirred vigorously for several hours. Under 
these reaction conditions we produced the desired acid in very high yields. With the 




Table 2: Conditions screened for the conversion of methyl ester to desired acid. 
Reagent Solvent Time Temperature Results 
LiOH THF 16 hr 24 °C No reaction 
LiOH THF 72 hr 100 °C Decomposition 
Me3SnOH DCE 24 hrs 60 °C No Reaction 
Me3SnOH DCE 72 hrs 90 °C No Reaction 
LiCl DMF 10 mins Microwave 15% yield  
(Me2AlTeMe)2 DCM 6 hrs 24 °C 85% yield 
 
3.6.3 Barton Decarboxylation 
 After an extensive literature search, we decided to try Barton decarboxylation 
conditions first. Barton decarboxylations have been used extensively in total synthesis, 
and remain one of the top methods for decarboxylation.90-95 These conditions call for the 
conversation of the carboxylic acid to the thiohydroxamate ester. The ester is then 
warmed in the presence of a hydrogen donor resulting in reductive decarboxylation.96,97 
There are many different conditions that can be used to form the thiohydroxamate and 
also a number of different conditions can be used to promote the radical 
decarboxylation.98,99 We attempted a number of different Barton decarboxylations using 
various conditions. (Scheme 42) The first Barton reaction we tried utilized a DCC 
coupling to afford thiohydroxamate ester 162, which was then treated with AIBN and 
 
 53 
HSnBu3. Attempts were also made to convert acid 161 to the corresponding acid 
chloride, which was then used in situ to form the desired thiohydroxamate ester 162. 
The ester was then treated with t-BuSH and irradiated with a desk lamp. Finally, we 
attempted the formation of the mixed anhydride, which was then used to form 
thiohydroxamate ester 162. This ester was then treated with t-BuSH and irradiated with 
a desk lamp. Unfortunately all of these reactions resulted in a complex mixture of 
products from which we were never able to isolate our desired product.  
 
Scheme 42: Attempted decarboxylation of 160. 
 It should be noted that thiohydroxamate esters produced under these reaction 
conditions were not isolated because of their high reactivity. These esters are extremely 



























































































purification of such esters is rarely attempted. These conditions presented us with a 
difficult problem. The reactions were clearly failing, but it was nearly impossible to 
pinpoint where the failure was occurring. In an effort to identify the step in which the 
problem arose, we decided to employ different reaction conditions.  
3.6.4 Modified Barton Decarboxylations 
 A few different Barton modifications have been published.100 We decided to use a 
modification developed by Hasebe and co-workers in which benzophenone oxime 
esters are employed in the place of thiohydroxamate esters.101 Unlike thiohydroxamate 
esters, benzophenone oxime esters can be isolated, purified and stored under ambient 
temperatures for months at a time.102 If we were able to isolate the desired 
benzophenone oxime ester, then we would be able to screen a number of different 
decarboxylation conditions.  
 The desired benzophenone oxime 164 could be synthesized in one step from 
acid 161. First, we tried to couple acid 161 with benzophenone imine using DCC and 
DMAP. Secondly, we tried to form the mixed anhydride of 161 followed by treatment 




Scheme 43: Attempted formation of benzophenone oxime ester 164. 
We believe that the formation of both esters 162 and 164 was unsuccessful because of 
steric interactions. Ester 160 was unreactive, and conversation to acid 161 required a 
special reagent used in hindered systems. Although we only screened a few reaction 
conditions for the formation of 162 and 164, we believed that screening alternative 
conditions would result in the same outcome. Due to the steric constraints of both the 
Barton reagent and the benzophenone imine, we believed that coupling of either 
reagent would be impossible, and we decided to screen other known decarboxylation 
conditions. 
3.6.5 Other Decarboxylations 
 Since we had been successful at converting the ester 160 to acid 161 using a 
methyltellurate reagent, we believed that we might be able to access a selenoester 
using similar reaction conditions.103-105 We made the corresponding dimethyl aluminum 
selenide reagent and added it to acid 161 in DCM at room temperature. After stirring at 

































































warmed to 30 °C overnight. Unfortunately, even under these conditions no desired 
product was isolated. (Scheme 44) Since these conditions were not working we decided 
to try a less conventional method of decarboxylation. 
 
Scheme 44: Attempted formation of selenoester 165. 
 In the next attempt, we wanted to try decarboxylation using photogenerated 
cation radical chemistry developed by Hatanaka and co-workers.106  Acid 161 was 
treated with Phen, DCB, t-DDSH in MeCN and H2O. The resulting solution was then 
irradiated with a 400W high-pressure mercury lamp for 24 hours. (Scheme 45) 
Unfortunately, none of the desired decarboxylated product 163 was isolated. We did, 
however, recover an undesired side product 166. 
 
Scheme 45: Attempted formation of 163 using photogenerated radical conditions.  
 Since all of the previous decarboxylations failed, alternative conditions were 
proposed. The classic Hunsdiecker reaction involves treatment of a carboxylic acid with 
silver oxide to form the corresponding silver salt. The silver salt is then treated with one 


























































the Hunsdiecker reaction is that the silver salt must be very pure and dry. To avoid this 
problem, we decided to try both the Cristol-Firth modification109 and the Suarez 
modification.110 First, we treated acid 161 with HgO and Br2 in dibromomethane but 
never observed any of the desired product (167). Next, we treated acid 161 with 
PhI(OAc)2, Cu(OAc)2 and pyridine in benzene. Under these conditions we were also 
unable to isolate any of our desired product (168). (Scheme 46) 
 
Scheme 46: Attempted modified Hunsdiecker reactions. 
Given that all of these attempts at the decarboxylation were unsuccessful, we 
decided to look at the problem from a different perspective. Up until this point, we had 
attempted decarboxylation using various radical conditions on our acid moiety. 
Treatment of our system as an amino acid, rather than an independent carboxylic acid, 
presented alternative decarboxylation conditions which we believed would be more 
successful.  It has been previously demonstrated that tertiary α-amino acid derivatives 
such as  169 can undergo clean decarboxylations by activation of the carboxylic acid 








































Scheme 47: Activation and decarboxylation of α-amino acids derivatives. 
There are a number of different ways to activate the carboxylic acid moiety.111-115 
One such method was used by Golding and co-workers.116 Using these conditions, we 
treated acid 161 with NBS in hopes of promoting the decarboxylated imine, which we 
then tried to reduce by treatment with excess NaBH4. We did not see any of our desired 
product (163). We did, however, isolate the undesired spirooxindole 172. (Scheme 48) 
 
Scheme 48: Attempted decarboxylation of 161. 
Although our initial attempts failed, we still wanted to screen conditions for the 
decarboxylation of α-amino acids. After searching the literature, we chose conditions 
used by Bermejo-Gonzalez and co-workers in their synthesis of indolizidine 
alkaloids.117,118 We treated acid 161 with DPPA and TEA in toluene. The reaction was 
then warmed to 100 °C for 16 hours. After workup we isolated our decarboxylated 
alkene 168 in a 41% yield. With the desired alkene in-hand, we turned our attention to 
reduction of alkene 168 to 163. (Scheme 49) However, all of the conditions that we have 



















































difficult, we were working on a concurrent plan that might allow us to readily 
decarboxylate.   
 
Scheme 49: Decarboxylation of 161 with DPPA to afford 168. 
3.7 Concurrent Route for Decarboxylation 
 We proposed that the decarboxylation was difficult because of sterics found in 
the pentacyclic ring system. We believed that changing the protecting group on the 
amine would reduce steric strain, thereby allowing us readily decarboxylate. We decided 
to revisit the retrosynthetic analysis shown in Scheme 50. We believed that we could 
access the exact pentacyclic core 82 via a decarboxylation, followed by an oxidative 
rearrangement of 173. Next, we could access acid 173 via hydrolysis of ester 174. 
Although traditional hydrolysis conditions were unsuccessful in previous studies, we 
believed that reducing the size of the substituent on the amine would make the acid 
more accessible. The desired ester could come from a one-pot reduction of both the 
amide and formate moieties present in intermediate 175.  We believed that we could 




























Scheme 50: Revised late stage retrosynthetic analysis. 
 In the forward direction, the synthesis starts with protection of the free amine as 
the formate. After optimization we were able to get the desired formate as the major 
product by keeping the reaction at -20 °C for 5 hours.119-121 (Scheme 51) 
 
Scheme 51: Formation of formate 176. 
With the desired formate in-hand, we needed to reduce 176 to the methylamine 177. 
We found that treatment of 176 with BMS in THF at ambient temperature for 16 hours 





































































LiOH and THF at reflux did not result in the formation of acid 178. This suggests that 
even after the reduction of the formate, the ester remains hindered and is unable to 
undergo hydrolysis. (Scheme 52) 
 
Scheme 52: Attempted synthesis of acid 178. 
3.8 Future Directions  
Although we were able to form the desired decarboxylated intermediate 168, 
many questions remain unanswered. In our first synthetic route, the reduction of alkene 
168 to 163 remains a top priority. We plan on screening a number of different conditions 




























Scheme 53: Future plans for the late stage synthesis of intermediate 163. 
We hope to combine both of our late stage synthetic approaches to access the 
desired pentacyclic core 181. Treatment of 177 with the methyltellurate reagent would 
provide us with acid 178. Using the previously described decarboxylation conditions, we 
could access alkene 179. Reduction of the double bond could provide intermediate 180. 
Finally, oxidation of intermediate 180 could provide the desired spirooxindole 181. 
(Scheme 54) 
 
Scheme 54: Future work for the formation of 181. 
It should be noted, that until the late stage synthesis has been established, we 
































































product. In our final synthetic efforts, we plan on utilizing the same synthetic strategy to 
convert anti 151 to the pentacyclic 82 framework of the PF1270s and the citrinadins.  
(Scheme 55) 
 






























































4.1 General Synthetic Considerations 
 All reagents were commercial grade and used without further purification unless 
otherwise noted.  Unless otherwise noted, all reactions were run under an argon 
atmosphere in flame or oven-dried glassware.  Reactions were monitored by thin layer 
silica gel chromatography (TLC) using 0.25 mm silica gel 60 F plates with fluorescent 
indicator (Merck).  Products were purified via either flash column chromatography using 
silica gel grade 60 (230-400 mesh) purchased from Sorbent Technologies or 
preparative thin layer chromatography (1000 mm).  Acetonitrile (CH3CN), 
dichloromethane (CH2Cl2), diethyl ether (Et2O), N,N-dimethylformamide (DMF), 
methanol (MeOH), tetrahydrofuran (THF), toluene (PhMe), and triethylamine (Et3N) 
were all degassed with argon and passed through a solvent purification system 
containing alumina or molecular sieves.  1H-NMR spectra and 13C-NMR spectra were 
obtained on ROBOT Varian 300, 400, or 500 MHz NMR spectrometers.  NMR spectra 
were taken n CDCl3 (1H, 7.26 ppm; 13C, 77.0 ppm), CD3OD (1H, 3.31 ppm, 49.15 ppm), 
d6-DMSO (1H, 2.50 ppm, 13C, 39.51 ppm) and D2O (1H, 4.79 ppm) obtained from 
Cambridge Isotope Labs.  Mass spectra were obtained on Fisons VG Autospec using a 




4.2 Experimental Procedures 
ethyl 2-(2-oxopyrrolidin-1-yl)acetate (93): 
 
 
To a solution of Na (0.540 g, 23.5 mmol) refluxing in toluene (15 mL) was added 2-
pyrrolidinone 92 (2 g, 23.5 mmol) dropwise. The reaction mixture was stirred at reflux for 
one hour after the addition was complete. An additional 10 mL of toluene was added so 
that the slurry could be stirred. Ethyl bromoacetate 91 (3.92 g, 23.5 mmol) was added 
dropwise for 20 minutes and the reaction mixture was stirred for an additional hour. The 
reaction was then cooled to room temperature and filtered. The solvents were 
evaporated under reduced pressure. The desired product was purified by distillation 
(literature bp 108-113 °C at 1-2 mmHg) to afford a colorless oil (3.75 g, 93%).  
 
1H NMR (300 MHz, CDCl3) δ 4.13 (q, J = 7.2 Hz, 2H), 3.99 (s, 2H), 3.42 (t, J = 6.9 Hz, 






















3-azaheptane-1,7-dioic acid hydrochloride (94): 
 
A solution of pyrrolidinone 93 (1.33 g, 7.78 mmol) was dissolved in 6 M HCl (10 mL). 
The solution was then refluxed for 48 hours. The solution was then cooled to room 
temperature and concentrated. The residue was then dissolved in MeOH (5 mL) and 
concentrated three times. The off white solid (1.24g, 98%) was then taken on without 
any further purification.  
 
1H NMR (300 MHz, D2O) δ 3.68 (s, 2H), 3.11 (t, J = 7.7 2H), 2.498 (t, J = 7.2 Hz, 2H), 






























methyl 4-((tert-butoxycarbonyl)(2-methoxy-2-oxoethyl)amino)butanoate (95): 
 
Acetyl chloride (1.17 mL) was added to MeOH (10 mL) and the solution was stirred for 
15 minutes at room temperature. The diacid 94 (1.9 g, 9.6 mmol) was then added and 
the reaction mixture was refluxed for five hours. The resulting solution was then cooled 
to room temperature and concentrated under reduced pressure. The crude clear oil was 
then taken on without further purification.  
Boc2O (3.43 g, 15.4 mmol) in DCM (3.2 mL) was added dropwise to a solution of TEA 
(2.31 mL, 15.4 mmol) and diester (2.24 g, 11.8 mmol) in 28.8 mL of DCM. The reaction 
mixture was then stirred at ambient temperature for 16 hours. The reaction mixture was 
then diluted with DCM (50 mL) and was washed with 2 M aqueous citric acid two times. 
The organic phase was then washed with brine then dried over Na2SO4, filtered and 
concentrated to half volume. The organic phase was ran through a bed of silica gel and 
evaporated to yield a colorless oil (67% over 2 steps).  
 
1H NMR (300 MHz, (CD3)2SO) δ 3.90 (bs, 2H), 3.66 (s, 3H), 3.60 (s, 3H), 3.24 (t, J = 7.2 
2H), 2.3 (t, J = 7.2 Hz, 2H), 1.76-1.69 (m, 2H), 1.38 (s, 6H), 1.14 (s, 3H); 13C NMR (75 
































ethyl 4-((tert-butoxycarbonyl)(2-ethoxy-2-oxoethyl)amino)butanoate (95B): 
 
Acetyl chloride (1.63 mL) was added to EtOH (14.6 mL) and the solution was stirred for 
15 minutes at room temperature. The diacid 94 (2.62 g, 13.3 mmol) was then added and 
the reaction mixture was refluxed for five hours. The resulting solution was then cooled 
to room temperature, and concentrated under reduced pressure. The crude clear oil was 
then taken on without further purification.  
Boc2O (3.38 g, 14.6 mmol) in DCM (3.2 mL) was added dropwise to a solution of TEA 
(2.21 mL, 14.6 mmol) and diester (2.65 g, 12.2 mmol) in 32 mL of DCM. The reaction 
mixture was then stirred at ambient temperature for 16 hours. The reaction mixture was 
then diluted with DCM (50 mL) and was washed with 2 M aqueous citric acid two times. 
The organic phase was then washed with brine then dried over Na2SO4, filtered and 
concentrated to half volume. The organic phase was ran through a bed of silica gel and 
evaporated to yield a colorless oil (87% over 2 steps). 
 
1H NMR (300 MHz, CDCl3) δ 4.20-4.07 (m, 4H), 3.91 (s, 1H), 3.83 (s, 1H), 3.31 (q, J = 
14.4, 7.8 Hz, 2H), 2.33 (t, J = 8.7 Hz, 2H), 1.87-1.77 (m, 2H), 1.45, 1.42, 1.40 (all 



























1-tert-butyl 4-methyl 3-oxopiperidine-1,4-dicarboxylate (96) and 1-tert-butyl 2-
methyl 3-oxopiperidine-1,2-dicarboxylate (97) : 
 
Potassium tert-butoxide (176 mg, 1.58 mmol) was added over 10 minutes to an ice-
cooled, stirred solution of Boc diester 95 (500 mg, 1.58 mmol) in dry toluene (4 mL). 
After an additional 20 minutes, the reaction was acidified to pH 3 using 2 M aqueous 
citric acid and the organic layer was separated. The aqueous phase was extracted with 
DCM and the combined organic phases were washed with washed with brine, dried 
over Na2SO4, filtered and concentrated. The crude oil was purified via flash column 
chromatography (5% EtOAc/Hex to 25% EtOAc/Hex). 
 
1-tert-butyl 4-methyl 3-oxopiperidine-1,4-dicarboxylate (96):  
1H NMR (300 MHz, (CDCl3) δ 11.96 (s, 1H), 3.99 (s, 2H), 3.74 (s, 3H), 3.45 (t, 2H), 
2.30-2.27 (m, 2H), 1.43 (s, 9H). (47%) 
 
1-tert-butyl 2-methyl 3-oxopiperidine-1,2-dicarboxylate (97): 
1H NMR (300 MHz, (CDCl3) δ 11.09 (s, 1H), 5.21 and 5.22 (both bs, total 1H), 4.05-3.83 
(m, 1H), 3.76 (s, 3H), 3.48-3.28 (m, 1H), 2.48-2.35 (m, 2H), 1.96-1.83 (m, 2H), 1.44 (d, J 













































(2R,3S)-1-tert-butyl 2-methyl 3-hydroxypiperidine-1,2-dicarboxylate (98): 
 
To a stirred, fermenting suspension of dried bakersʼ yeast (288 mg) and sucrose (960 
mg) in tap water (9 mL) was added Boc ketone 97 (96 mg, 0.373 mmol). The reaction 
mixture was gently warmed to 30-32 °C. After 24 hours, the mixture was vacuum 
filtrated and re-filtered through Celite. The filtrate was then extracted with DCM 5 times. 
The combined extracts were washed with brine and then dried, filtered, and 
concentrated to give an oil (83 mg, 86%).  
 
1H NMR (300 MHz, (CD3)2SO, 300K) δ 4.87 (d, J = 4.8 Hz, 1H), 4.68 (d, J = 6.6 Hz, 
1H), 3.76-3.71 (m, 2H), 3.63 (s, 3H), 3.10 (dt, J = 12.6 Hz, 1H), 1.71-1.56 (m, 4H), 1.39 
(s, 9H); 13C NMR (75 MHz, CDCl3) δ 172.6, 155.4, 80.7, 68.9, 58.6, 57.4, 52.4, 41.4, 


















1H NMR, 300 MHz, (CD3)2SO, 300K , filename: ms291ht 
 









(2R,3S)-methyl 3-hydroxypiperidine-2-carboxylate (99): 
  
To a stirred solution of Boc amine 98 (80.6 mg) in DCM (3 mL) at 0 °C was added TFA 
(230 μL). The reaction was warmed to ambient temperature and was stirred for an 
additional 5 hours. The reaction mixture was then concentrated under reduced pressure. 
The residue was then dissolved in EtOAc and quenched with NaHCO3 (pH 9). The 
organic phase was then separated and the aqueous was then extracted with EtOAc. 
The combined extracts were dried, filtered over Na2SO4, and concentrated under 
reduced pressure.  
 
1H NMR (300 MHz, (CDCl3) δ 4.20 (bs, 1H), 3.76 (s, 3H), 3.15 (d, J = 12.1 Hz, 1H), 2.66 



























To a solution of indole (5 g, 42.68 mmol) in 100 mL of DMF stirring at 0 °C was added 
N-Chlorosuccinimide (5.69 g, 42.68 mmol). The yellow solution was stirred at room 
temperature in an inert atmosphere overnight resulting in brown solution. This was then 
quenched with a saturated solution of brine and extracted with ether. The combined 
organic phases were then washed with water, dried over magnesium sulfate and 
concentrated under reduced pressure. The resulting brown solid was purified via flash 
column chromatography (5% ETOAc/hexanes) to afford a white crystalline solid (5.70 g, 
88%). 
 
1H NMR (300 MHz, CDCl3) δ 8.05 (bs, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.37 (d, J = 8.7 Hz, 























To a solution of prenyl-9-BBN (0.5M) at room temperature was added TEA (9.58 mL, 
71.59 mmol) and then solid chloroindole 103 (3.34 g, 22.03 mmol). The yellow solution 
was then stirred for an additional 3 hours at room temperature. This reaction was then 
quenched with saturated NaHCO3 and then extracted with ether. The combined organic 
phases were then washed with H2O, brine, dried over Na2SO4, and concentrated under 
reduced pressure. The crude yellow oil was then purified via flash column 
chromatography (EtOAc/hexanes 2:8) to afford a pale yellow foam (3.45 g, 84%). 
 
1H NMR (300 MHz, CDCl3) δ 7.89 (bs, 1H), 7.57 (d, J = 8.1 Hz, 1H), 7.34 (d, J = 8.1 Hz, 
1H), 7.19-7.05 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 146.3, 136.1, 128.7, 121.5, 120.3, 
119.8, 112.4, 110.7, 98.1, 38.4, 27.6; HRMS (ESI/APCI) calcd for C8H8N (M+H) 










1H NMR, 300MHz, CDCl3, filename: ms327pure 
 






N, N-dimethyl-1-(2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)methanamine (105):  
  
To formaldehyde (4.04 mL, 54.29) in 100 mL AcOH was added diethylamine (25.85 mL, 
45.08) dropwise. The resulting solution was then stirred at room temperature for 10 
minutes. Reverse prenylated indole 104 (6.67 g, 36.6 mmol) dissolved in 20 mL of 
AcOH was then added and the resulting mixture was stirred overnight.  The reaction 
mixture was then quenched with 2 M NaOH (pH of at least 10) and extracted with ether. 
The combined ether extracts were then dried over magnesium sulfate, filtered and 
concentrated under reduced pressure. The resulting yellow oil (6.66 g, 74%) was then 
taken on without further purification. 
 
1H NMR (300 MHz, CDCl3) δ 7.93 (bs, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.29-7.25 (m, 1H), 
7.14-7.05 (m, 2H), 6.17 (dd, J = 17.4, 10.5Hz, 1H), 5.18 (dd, J = 9.1, 1.3 Hz, 1H), 5.18 
(q, J = 1.4, 1.1 Hz), 3.59 (s, 2H), 2.27 (s 6H), 1.58 (s 6H); 13C NMR (75 MHz, CDCl3) δ 
146.4, 141.4, 134.0, 130.6, 121.3, 119.4, 112.1, 110.4, 109.0, 62.5, 54.1, 45.6, 39.5, 











1H NMR, 300 MHz, CDCl3, filename: ms328p 
 
 











The crude gramine 105 (3.33 g, 13.74 mmol) and benzophenone imine (4.04 g, 15.11 
mmol) were dissolved in 60 mL of MeCN. Then PBu3 was added to the reaction mixture 
at room temperature. The resulting solution was refluxed overnight at 110 °C. This 
mixture was then concentrated under reduced pressure. The crude brown oil was then 
purified via flash column chromatography (EtOAc/hexanes 1:9) to afford a pale yellow 
foam (3.99 g, 63%).     
 
1H NMR (300 MHz, CDCl3) δ 7.94-6.856 (m, 14H), 7.69 (bs, 1H), 5.91 (dd, J = 17.4, 
10.5 Hz, 1H), 5.14- 5.01 (m, 2H), 4.53 (t, J = 13.2, 1H), 4.25-4.22 (m, 2H), 3.60 (d, J = 
6.9, 2H), 1.41 (s, 3H), 1.38 (s, 3H), 1.29 (t, J = 6.9, 3H); 13C NMR (75 MHz, CDCl3) δ 
172.8, 170.1, 146.3, 139.5, 137.8, 136.2, 134.2, 132.7, 130.3, 130.2, 129.1, 128.6, 
128.1, 128.0, 127.8, 121.4, 119.6, 119.1, 111.8, 110.2, 107.5, 66.9, 61.1, 39.3, 29.0, 



















1H NMR, 300 MHz, CDCl3, filename: ms329pure 
 











ethyl 2-amino-3-(2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)propanoate (107): 
 
To imine 106 (6.38 g, 13.7 mmol) was dissolved in THF (100 mL) and cooled to 0 °C. 
Then 2 M HCl (6.87 mL) was slowly added to the reaction mixture. The reaction mixture 
turned bright red and was allowed to warm to ambient temperature over 20 minutes. 
The THF was then evaporated under reduced pressure. The resulting aqueous layer 
was then basified with NaHCO3 and extracted with DCM. The pale yellow oil (2.52 g, 
62%) was then purified via column chromatography (EtOAc/Hex 1:1 to MeOH/DCM 
1:9). 
 
1H NMR (300 MHz, CDCl3) δ 7.96 (bs, 1H), 7.56 (d, J = 7.5 Hz, 1H), 7.29-7.26 (m, 1H), 
7.15-7.05 (m, 2H), 6.13 (dd, J = 17.4, 10.5 Hz, 1H), 5.21- 5.15 (m, 2H), 4.18-4.05 (m, 
3H), 3.36-3.30 (m, 1H), 3.10-3.01 (m, 1H), 1.57 (s, 6H), 1.17 (t, J = 14.1 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 175.7, 146.3, 140.9, 134.7, 129.9, 121.6,119.4, 118.6, 112.0, 
110.8, 106.8, 61.1, 56.2, 39.4, 31.6, 28.2, 28.1, 14.3; HRMS (ESI/APCI) calcd for 


















1H NMR, 300 MHz, CDCl3, filename: ms330pure 
 
13C NMR, 75M Hz, CDCl3, filename: ms330purecarbon 
 











To amine (0.4 g, 1.33 mmol) dissolved in dioxanes was added Boc2O (0.30g, 1.39 
mmol) followed by 1 M NaOH (1.33 mL). The reaction mixture was stirred at ambient 
temperature for 3 hours, then was quenched with saturated citric acid. The reaction was 
then extracted with EtOAc and dried, filtered, and concentrated under reduced pressure. 
The pale yellow foam was purified via column chromatography (EtOAc/Hexanes 2:8) to 
provide a pale yellow foam (0.501 g, 94%).  
 
1H NMR (300 MHz, CDCl3) δ 7.97 (bs, 1H), 7.50 (d, J = 7.5 Hz, 1H), 7.26 (d, J = 8.1 Hz, 
1H), 7.14-7.04 (m, 2H), 6.14 (dd, J = 17.4, 10.5 Hz, 1H), 4.16-3.88 (m, 2H), 3.34- 3.18 













yl)propanoic acid (80): 
 
To ester 108 (2.94 g, 6.16 mmol) dissolved in 2:1 H2O: THF (41:20 mL) was added 
LiOH (2.85 g, 61.6 mmol). The resulting solution was stirred overnight at ambient 
temperature. The biphasic reaction mixture was then concentrated under reduced 
pressure. The resulting solution was then quenched with 1 M KHSO4 to pH 2. The 
aqueous was then extracted 5 times with EtOAc, dried over Na2SO4, filtered and 
concentrated under reduced pressure to provide a pale white solid (2.15 g, 93%).   
 
1H NMR (300 MHz, CD3OD) δ 7.52 (d, J = 7.6 Hz, 1H), 7.27 (d, J = 8 Hz, 1H), 7.02-6.93 
(m, 2H), 6.21 (dd, J = 17.6, 10.8 Hz, 1H), 5.16- 5.08 (m, 2H), 4.39 (t, J = 8.8 Hz, 1H), 
3.40 (dd, J = 14.8, 6 Hz, 1H), 3.09 (dd, J = 14.4, 8.8 Hz, 1H), 1.56 (s, 6H), 1.26 (s, 6H) 
1.04 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 174.86, 156.09, 146.37, 140.41, 135.01, 

















1H NMR, 400 MHz, CD3OD, filename: AcidTrypBocRevprenylPROTON 












(S)-methyl 2-((diphenylmethylene)amino)-3-(1H-indol-3-yl)propanoate (188): 
 
Tryptophan 187 (30 g, 117.78 mmol) was taken up in 471 mL of DCM. To this solution, 
benzophenone imine (19.33 mL 117.78 mmol) was added. The resulting solution was 
stirred at room temperature for 24 hours under argon. The reaction mixture was filtered 
to remove NH4Cl and evaporated to dryness on a rotary evaporator. The residue was 
taken up in 100 mL of ether, filtered, washed with 50 mL of water, and dried with Na-
2SO4. The white solid was purified via recrystallization from hexane/ethylacetate. 
 
1H NMR (300 MHz, CDCl3) δ 7.94 (bs, 1H), 7.69 (d, J = 6.9, 2H), 7.40-7.09 (m, 14H), 
6.97-6.89 (m, 1H), 4.55-4.40 (m, 1H), 3.71 (s, 3H), 1.38 (s, 3H), 3.50-3.44 (m, 2H); 13C 
NMR (75 MHz, CDCl3) δ 129.0, 128.3, 127.7, 123.3, 122.0, 119.4, 118.9, 112.0, 111.0, 





















1H NMR, 300 MHz, CDCl3, filename: ms686p 
 















To a cold (-78 °C) solution of tryptophan 188 (1.99 g, 5.70 mmol) and TEA (0.95 mL, 
6.84 mmol) in 20 mL of THF was added tert-butyl hypochlorite (0.83 mL, 6.84 mmol). 
After the solution was stirred for 0.5 h at -78 °C, a 1.0 M solution of prenyl-9-BBN (11.4 
mL, 11.4 mmol) in THF was added dropwise. The solution was allowed to warm slowly 
over 6 h to ambient temperature, after which 5 mL of a saturated solution of K2CO3 (aq) 
was added. The layers were separated, and the aqueous layer was extracted with ethyl 
acetate (3x10 mL). The organics were combined, dried (MgSO4), filtered, and 
concentrated in vacuum.  
 
1H NMR (CDCl3, 300 MHz) δ 7.93 (s, 1H), 7.68 (m, 2H), 7.60 (m, 2H), 7.26 (d, J = 7.9 
Hz, 1H), 7.12 (d, J = 8.1 Hz, 1H), 6.9 (t, J = 7.1 Hz, 1H), 6.71 (t, J = 7.1 Hz, 1H), 6.19 
(dd, J = 10.5, 17.5 Hz, 1H), 5.18 (m, 3H), 3.87 (dd, J = 3.8, 15.2 Hz, 1H), 3.77 (s, 3 H), 
3.67 (dd, J = 11.3, 15.2 Hz, 1H), 1.57 (s, 6H); HRMS (ESI/APCI) calcd for C25H24N2O4 































(S)-methyl 2-amino-3-(2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl)propanoate (190): 
 
Benzophenone 189 (2.19 g, 5.01 mmol) was dissolved in a THF (37 mL) and then 
cooled to 0 °C. Then 1 M HCl (12.5 mL) was added and the reaction mixture was stirred 
at 0 °C for an additional 15 minutes. The reaction was then warmed to room 
temperature and then stirred for an additional 30 minutes. The solvent was then 
evaporated, saturated NaHCO3 was added, and the aqueous solution was extracted 
three times with EtOAC. The combined organic phases were then dried over anhydrous 
Na2SO4, filtered and then concentrated under reduced pressure. The crude amine was 

















To a solution of free amine (1.74 g, 6.4 mmol) dissolved in dioxanes (32.5 mL) at room 
temperature was added di-tert-butylcarbonate (1.48 g, 6.8 mmol) and 1M NaOH (3.25 
mL). The mixture was stirred at room temperature for 2.5 hours. The solvent was then 
evaporated, saturated KHSO4 was added and the aqueous solution was then extracted 
three times with ethyl acetate. The combined organics were then dried over Na2SO4 and 
concentrated. The crude product was then purified by means of silica gel 
chromatography, using EtOAc/hexanes (1:9) as the eluent to yield 2.49 g of pure 
protected amine (25%, over 3 steps). 
 
1H NMR (CDCl3, 300 MHz) δ 7.93 (bs, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.19-7.04 (m, 2H), 
6.14 (dd, J = 10.5, 17.5 Hz, 1H), 5.20 (m, 3H), 4.60-4.50 (m, 1H), 3.56 (s, 3H), 3.34-
3.17 (m, 2H), 1.57 (s, 6H), 1.32 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 211.1, 199.5, 
173.2, 146.2, 140.6, 134.3, 129.9, 121.6, 119.5, 118.5, 112.4, 110.5, 106.0, 79.7, 77.3, 
















1H NMR, 300 MHz, CDCl3, filename: ms541p 
 








cis-3-hydroxypiperidine-2-carboxylic acid (100): 
 
In a high-pressure vessel, the acid (6 g, 43.1 mmol) was dissolved in 90 mL of H2O and 
then degassed with argon for 15 minutes. To this solution, NH4OH (12 mL) was added  
followed by Rh/C (2.5 g, 4% mass eq.). The solution was then pressurized to 80 psi with 
H2 and stirred for 72 hours. The mixture was then filtered through a bed of Celite, rinsed 
with EtOAc, concentrated and then lyophilized overnight. The pale pink powder (5.34 g, 













cis-ethyl 3-hydroxypiperidine-2-carboxylate (81): 
 
To EtOH (116 mL) at 0 °C was added SOCl2 (6.33 mL, 87.2 mmol). The resulting 
solution was then stirred for 15 minutes at ambient temperature. After which, the 
pipecolic acid 100 (4.22g, 29.0 mmol) was then added to the reaction flask. The reaction 
mixture was stirred at 80 °C for 24 hours. The reaction was then cooled to room 
temperature and concentrated under reduced pressure. The resulting white solid was 
then dissolved in EtOH and concentrated again. This was repeated three more times. 
The resulting white solid was then treated with NaHCO3 (pH of 10) and extracted with 
DCM. The organics were then combined, dried over NaSO4, filtered and then 
concentrated. The crude oil product was then purified by means of silica gel 
chromatography, using DCM-MeOH (9:1) as the eluent to yield 3.67 g of pure protected 
amine (73%). 
 
1H NMR (CDCl3, 400 MHz) δ 4.25-4.10 (m, 3H), 3.40 (d, J = 1.5), 3.07 (d, J = 11.7 Hz, 





























(2S,3R)-methyl 3-hydroxypiperidine-2-carboxylate (81B) 
 
To MeOH (60 mL) at 0 °C was added SOCl2 (3.14 mL, 43.1 mmol). The resulting 
solution was then stirred for 15 minutes at ambient temperature. After which, the 
pipecolic acid 100 (2.0 g, 14.3 mmol) was then added to the reaction flask. The reaction 
mixture was stirred at 80 °C for 24 hours. The reaction was then cooled to room 
temperature and concentrated under reduced pressure. The resulting white solid was 
then dissolved in MeOH and concentrated again. This was repeated three more times. 
The resulting white solid was then treated with NaHCO3 (pH of 10) and extracted with 
DCM. The organics were then combined, dried over NaSO4, filtered and then 
concentrated. The crude oil product was then purified by means of silica gel 
chromatography, using DCM-MeOH (9:1) as the eluent to yield 1.97 g of pure protected 
amine (73%). 
 
1H NMR (CDCl3, 400 MHz) δ 4.06 (s, 1H), 3.66 (s, 1H), 3.33 (s, 1H), 3.00 (d, J = 2.65 





























To a solution of acid 80 (1.22 g, 3.29 mmol) and methyl ester 99 (0.570 g, 3.29 mmol) in 
MeCN at 0 °C was added HATU (1.87 g, 4.94 mmol), then DIPEA (2.29 mL, 13.16 
mmol).  The mixture was stirred overnight at room temperature and concentrated under 
reduced pressure. The residue was then purified by means of silica gel 
chromatography, using EtOAc/hexanes (2:8) as the eluent to yield 1.02 g of pure yellow 
foam (63%). 
1H NMR (CDCl3, 400 MHz) δ 8.25 (bs, 1H), 8.09 (bs, 1H), 7.54 (t, J = 7.2 Hz, 1H), 7.25-
7.02 (m, 3H), 6.23-6.06 (m, 1H), 5.61 (m, 1H), 5.26-5.15 (m, 2H), 5.02 (bs, 1H), 4.32 (d, 
J = 5.4 Hz, 1H), 3.65 (s, 3H), 3.40-3.12 (m, 4H), 2.66 (m, 1H), 2.39 (bs, 1H), 2.21 (m, 
1H), 1.59 (m, 6H), 1.43 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 172.7, 171.7, 171.0, 145.5, 
140.6, 134.0, 130.1, 122.0, 121.9, 119.8, 118.7, 112.8, 112.6, 110.6, 110.5, 105.6, 
105.4, 79.6, 79.4, 68.1, 67.8, 59.2, 55.5, 52.8, 52.6, 50.4, 50.2, 43.2, 39.3, 39.3, 31.1, 
31.0,  29.6, 29.4, 28.5, 28.0, 27.9, 22.3, 22.0; HRMS (ESI/APCI) calcd for C28H39N3O6 


























1H NMR, 300 MHz, CD3OD, filename: ms316pure 
 














To a solution of acid 80 (841 mg, 2.25 mmol) and methyl ester 81 (391 mg, 2.25 mmol) 
in MeCN at 0 °C was added HATU (1.29 g, 3.38 mmol), then DIPEA (1.57 mL, 9.03 
mmol).  The mixture was stirred overnight at room temperature and concentrated under 
reduced pressure. The residue was then purified by means of silica gel 


























To a solution of protected amine 109B (970 mg, 1.83 mmol) in 3 mL of DCM at 0 °C 
was added 3 mL of TFA. This was then stirred for 1 hour at room temperature. The 
resulting brown solution was then concentrated to dryness and the residue was treated 
with a saturated solution of NaHCO3. The solution was stirred for 60 minutes at room 
temperature and then extracted with DCM. The combined organic phases were washed 
with brine, dried over Na2SO4, filtered and then concentrated to dryness. The residue 
was then purified by means of silica gel chromatography, using MeOH/DCM (1:19) as 























To a solution of protected amine 109 (970 mg, 1.83 mmol) in 3 mL of DCM at 0 °C was 
added 3 mL of TFA. This was stirred for 1 hour at room temperature. The resulting 
brown solution was then concentrated to dryness and the residue was treated with a 
saturated solution of NaHCO3. The solution was then stirred for 60 minutes at room 
temperature and extracted with DCM. The combined organic phases were then washed 
with brine, dried over Na2SO4, filtered and then concentrated to dryness. The residue 
was then purified by means of silica gel chromatography, using MeOH/DCM (1:19) as 
the eluent to yield 632 mg of pure yellow foam (67%). 
 
Trans: 1H NMR (CDCl3, 400 MHz) δ 7.92 (bs, 1H), 8.09 (bs, 1H), 7.57 (d, J = 7.2 Hz, 
1H), 7.24 (d, J = 7.5 Hz, 1H), 7.14-7.05 (m, 2H), 6.15 (dd, J = 17.4, 10.5 Hz, 1H), 5.58 
(d, J = 8.7 Hz, 1H), 5.26-5.17 (m, 3H), 5.03 (m, 1H), 4.23-4.03 (m, 3H), 3.40-3.17 (m, 
4H), 2.64 (t, J = 13.2 Hz 1H), 2.39 (bs, 1H), 1.44 (s, 6H).  
Cis: 1H NMR (CDCl3, 400 MHz) δ 8.04 (bs, 1H), 7.54 (d, J = 7.2 Hz, 1H), 7.24 (m, 1H), 
7.14-7.02 (m, 2H), 6.20 (dd, J = 17.4, 10.5 Hz, 1H), 5.67 (d, J = 8.7 Hz, 1H), 5.22-5.15 
(m, 2H), 5.06 (m, 1H), 4.28 (d, J = 5.4 Hz, 1H), 4.21-4.05 (m, 3H), 3.41-3.12 (m, 3H), 




























145.6, 141.0, 133.9, 130.2, 121.9, 119.9, 118.7, 112.9, 110.6, 105.4, 79.4, 68.1, 62.0, 
59.1, 50.3, 38.9, 31.3, 29.5, 28.5, 28.0, 27.5, 22.06, 14.0; HRMS (ESI/APCI) calcd for 
C22H27N3O3 (M+H) 381.4681, found 381.4692.  
 
 
1H NMR, 300 MHz, CDCl3, filename: mscoupledTS1 
 
 























13C NMR, 75 MHz, CDCl3, filename: ms358carbon 
 
 112 
7b-butyl-7bH-benzo[d][1,2]oxazireno[2,3-b]isothiazole 3,3-dioxide (111): 
  
 
In a three neck round bottom fitted with an addition funnel was added imine (0.5 g, 2.20 
mmol), 30 mL of DCM and 30 mL of saturated K2CO3 solution. The addition funnel was 
then charged with m-CPBA (0.58 g, 3.35 mmol) in 20 mL of DCM. The m-CPBA was 
added dropwise over 30 minutes at room temperature. Once the addition was finished 
the reaction mixture was stirred for an additional 30 minutes at room temperature. The 
organic phase was then separated from the aqueous phase using a separatory funnel. 
The organic phase was then washed with saturated Na2SO3, saturated NaHCO3, and 
brine. Finally the organic phase was dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude material was then purified via column chromatography 






















To a solution of DKP 110 (70.6 mg, 0.185 mmol) dissolved in 3.7 mL of DCM at ambient 
temperature,  was added oxaziridine (88.5 mg, 0.370 mmol).  The reaction mixture was 
allowed to stir at ambient temperature for 48 hours and then was concentrated. The 
crude oil was then purified via column chromatography (MeOH/DCM 3/97) to afford a 
pale yellow foam (44.5, 61%). 
 
1H NMR (300 MHz, CDCl3) δ 7.22-7.10 (m, 1H), 6.85-6.72 (m, 0.7H), 6.61 (d, J = 7.8 
Hz, 0.3H), 6.42-6.26 (m, 1H), 5.241-5.028(m, 1H), 4.56-4.28 (m, 1H), 3.81 (bs, 0.3H), 
3.63-3.56 (m, 0.5H), 2.87-2.60 (m, 1H), 2.53-2.44 (m, 1H), 2.102-1,89 (m, 1H), 1.81-
1.51 (m, 1H), 1.45 ( s, 1.17H), 1.33 (s, 1.87H), 1.26 (d, J = 11.1 Hz, 2H); HRMS 













































The alcohol 112 (129.2 mg, 0.325 mmol) was dissolved in 7 mL of DCM under argon. 
To the reaction was added DEAD (0.15 mL, 0.975mmol) and PBu3 (0.24 mL, 0.975 
mmol). The mixture was then stirred at room temperature for 16 hours and was 
concentrated to afford a brown oil. The crude oil was then submitted to purification via 
column chromatography (MeOH/DCM 3/97) and provided a pale yellow foam (59.7 mg, 
48%). 
  
1H NMR (300 MHz, CDCl3) δ 7.26.7.25 (m, 2H), 6.81-6.72 (m, 2H), 6.61 (bs, 1H), 6.37 
(q, J = 17.7, 10.8 Hz, 1H), 6.20 (bs, 1H), 5.13 (q, J = 17.7, 10.8 Hz, 2H), 4.52 (t, J = 7.5 
Hz, 1H), 4.31-4.07 (m, 4H), 3.03-2.78 (m, 3H), 2.28-2.17 (m, 2H), 1.91-1.83 (m, 1H), 








































To a flame dried flask fitted with a reflux condenser was added alcohol derivative 110 
(470 mg, 1.232 mmol) and 24.6 mL of MeCN. Then DEAD (0.582 mL, 3.69 mmol) was 
added and the mixture was stirred for 15 minutes at room temperature. PBu3 (0.923 mL, 
3.69 mmol) was added to the reaction flask and the resulting solution was refluxed at 90 
°C overnight. The solution was then allowed to cool to room temperature and then 
concentrated to afford a crude brownish oil. The residue was purified by means of silica 
gel chromatography, using EtOAc/hexanes (4:1) as the eluent to yield 447 mg of pure 
white foam (89%).  
 
1H NMR (CDCl3, 300 MHz) δ 8.12 (bs, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 8.1 Hz, 
1H), 7.18-7.07 (m, 2H), 6.36 (t, J = 4.2 Hz, 1H), 6.15 (dd, J = 17.4, 10.2 Hz, 1H), 5.73 
(bs, 1H), 5.18-5.12 (m, 2H), 4.45 (d, J = 10.2 Hz, 1H), 3.99-3.90 (m, 1H), 3.73-3.65 (m, 
2H), 3.26-3.18 (m, 1H), 2.30-2.25 (m, 2H), 1.91-1.69 (m, 3H), 2.39 (bs, 1H), 1.53 (s, 
6H); 13C NMR (CDCl3, 75 MHz) δ 164.0, 158.8, 145.9, 141.8, 134.5, 129.0, 128.7, 
122.2, 120.2, 118.3, 117.3, 112.5, 110.9, 104.6, 55.7, 40.3, 39.2, 31.0, 27.9, 22.4, 20.2; 
























1H NMR, 300 MHz, CDCl3, filename: ms771p 
  













Diels-Alder Cycloadducts (124 and 123): 
 
To a solution of enamide 122 (463.6 mg, 1.127 mmol) in MeOH (102 mL) at 0 °C, was 
added 20% aqueous KOH (25.5 mL). The resulting reaction mixture was stirred at room 
temperature for 5 hours. The MeOH was evaporated under reduced pressure and the 
resulting residue was diluted with DCM, and quenched saturated aqueous NH4Cl. The 
organic layer was separated from the aqueous layer using a separatory funnel. The 
aqueous layer was then extracted 5 times with DCM (25 mL). The combined organic 
extracts were dried over Na2SO4, filtered and then concentrated. Total combined yield 
400.2 mg, 86% yield. syn: 236.9 mg anti: 163.3 mg (1.5:1).  
 
Mixture: 1H NMR (300 MHz, CDCl3) δ 7.45-7.740 (m, 2H), 7.26-7.20 (m 2H), 7.10 (m, 
4H), 3.79 (d, J = 17.4 Hz, 1H), 3.70 (d, J = 12.9 Hz, 0.5H), 3.50-3.44 (m, 1H), 2.87 (d, J 
= 17.7 Hz, 1H), 2.63 (d, J = 15.3 Hz, 0.5H), 2.41-2.35 (m, 2H), 2.24-2.10 (m, 2H), 2.04-
1.85 (m, 1H), 1.23 (s, 1H), 1.15 (s, 1H); HRMS (ESI/APCI) calcd for C22H25N3O2 (M+H) 





























































To a mixture of amides 124 and 123  (82.5 mg, 0.225 mmol) in toluene (45 mL) at 0 °C, 
was added DIBAL (4.5 mL) dropwise. The reaction mixture was then stirred at room 
temperature overnight. Solid Na2SO4-9H2O was added and stirred for 60 minutes. The 
solids were filtered off and rinsed with EtOAc. The filtrate was concentrated under 
reduced pressure to afford a crude pale yellow solid. The crude solid was purified via 
column chromatography (MeOH/ DCM 1/99) to afford a white solid (63.5 mg, 80%).  
 
Anti: 1H NMR (400 MHz, (CD3)2CO) δ 9.90 (bs, 1H), 7.26-6.83 (m, 4H), 3.83-3.75 (m, 
1H), 3.39 (d, J = 10.4, Hz, 1H), 2.19 (s, 1H), 2.09-1.97 (m, 4H), 1.79-1.74 (m, 1H), 2.16 
(m, 2H), 1.42-1.38 (m, 3H), 1.34 (s, 3H), 1.24 (s, 3H), 1.17-1.08 (m, 3H); 13C NMR (100 
MHz, (CD3)2CO) δ 173.0, 128.8, 120.8, 118.4, 117.4, 110.5, 104.6, 103.9, 60.9, 55.2, 
54.7, 46.9, 34.4, 31.2, 30.1, 25.8, 23.5, 21.3, 18.2; HRMS (ESI/APCI) calcd for 



























Syn: 1H NMR (400 MHz, (CD3)2CO) δ 9.84 (bs, 1H), 7.22 (d, J = 8.0 Hz, 1H), 7.14 (d, J 
= 8.0 Hz, 1H), 6.93-6.81 (m, 2H), 3.50-3.35 (m, 1H), 3.11 (d, J = 13.2 Hz, 1H), 2.57-2.53 
(m, 1H), 2.27-2.20 (m, 2H), 1.74-1.67 (m, 1H), 1.60-1.53 (m, 1H), 1.40-1.35 (m, 3H), 
1.16 (s, 3H), 1.16-1.05 (m, 4H); 13C NMR (100 MHz, (CD3)2CO) δ 173.3, 141.6, 136.9, 
120.7, 118.3, 117.6, 110.5, 103.4, 98.3, 64.3, 58.0, 54.2, 54.0, 46.7, 34.5, 34.0, 30.7, 







1H NMR, 400 MHz, (CD3)2CO, filename: ms411ts/PROTON_001 
 
 














1H NMR, 400 MHz, (CD3)2CO, filename: ms411Bs/PROTON_001 
 

















To a solution of enamide 122 (830 mg, 2.28 mmol), and CsCO3 (3.72 g, 11.40 mmol) in 
DCM (22.8 mL) at ambient temperature, was added (CH3)3OBF4 (1.012 g, 6.84 mmol). 
The reaction mixture was stirred for an additional 6 hours, quenched with ice and 
extracted with DCM. The combined organic phases were dried over Na2SO4, filtered 
and then concentrated.   
 
1H NMR (300 MHz, CDCl3) δ 7.89 (bs, 1H), 7.57 (d, J = 8.1 Hz, 1H), 7.34 (m, 1H), 7.10-
6.99 (m, 2H), 6.13 (q, J = 17.4, 8.1 Hz, 1H), 5.73 (t, J = 3.9 Hz, 1H), 5.12 (q, J = 20.4, 
13.5 Hz, 2H), 4.60 (q, J = 8.4, 4.2 Hz, 1H), 4.043-3.97 (m, 1H), 3.64 (s, 3H), 3.33-3.14 
(m, 3H), 2.14-2.07 (m, 2H), 1.79-1.71 (m 2H), 1.59 (d, J = 3.3 Hz, 6H); 13C NMR (75 
MHz, CDCl3) δ 167.9, 146.5, 121.4, 119.7, 119.0, 112.0, 110.2, 110.0, 62.1, 53.2. 39.6, 
























1H NMR, 300 MHz, CDCl3, filename: ms426ts 
 














Diels-Alder Cycloadducts (139 and 140): 
 
To a solution of lactim ether 142 (600 mg, 1.589 mmol) in MeOH (127 mL) at 0°C, was 
added 20% aqueous KOH (37 mL). The mixture was then refluxed for 3 hours. The 
solution was then cooled to room temperature and concentrated. The resulting residue 
was then neutralized to pH 7 with KH2PO4, diluted with H2O and extracted with DCM. 
The combined organic extracts were dried over Na2SO4, filtered and then concentrated 
(Anti 1 to syn 1.20). 
 
Anti: 1H NMR (400 MHz, CDCl3) δ 7.63 (bs, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 
7.6 Hz, 1H), 7.09-7.00 (m, 2H), 3.86 (d, J = 16.8 Hz, 1H), 3.62 (s, 3H), 3.20 (d, J = 16.8 
Hz, 1H), 2.30-2.24 (m, 1H), 2.24-2.09 (m, 2H), 1.74-1.57 (m, 6H), 1.52 (d, J = 9.6 Hz, 
1H), 1.18 (s, 3H), 1.07 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 175.9, 170.3, 139.6, 
136.3, 128.0, 121.4, 119.1, 118.8, 110.2, 106.3, 65.2, 57.3, 24.0, 44.8, 39.3, 34.8, 33.7, 
28.5, 26.5, 25.2, 22.0, 18.2; HRMS (ESI/APCI) calcd for C23H27N3O2 (M+H) 378.2103, 
found 378.2171. 
Syn: 1H NMR (400 MHz, CDCl3) δ 7.63 (bs, 1H), 7.53 (d, J = 7.2 Hz, 1H), 7.15-7.04 (m, 


























2.39-2.34 (m, 1H), 2.16 (q, J = 10.4, 5.2 Hz, 1H), 1.52 (dd, J = 12.8, 5.2 Hz, 1H),  1.78-
1.66 (m, 6H), 1.44 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 175.9, 170.3, 139.6, 136.3, 
128.0, 121.4, 119.1, 118.8, 110.2, 106.3, 65.2, 57.3, 24.0, 44.8, 39.3, 34.8, 33.7, 28.5, 







1H NMR, 400 MHz, CDCl3, filename: msLacEthAnti 
 
 













1H NMR, 400 MHz, CDCl3, filename: LacEtherSynProton 
 
















To a solution of bicyclo adduct 139 (29.4 mg, 0.00779 mmol) in THF (0.779 mL) at 0 °C 
was added Ac2O (.147mL) and then 0.1 M aqueous HCl (0.779mL). The reaction was 
then stirred overnight in the cold room (4 °C). The reaction was then quenched with a 
saturated solution of NaHCO3 and extracted with EtOAc. The combined organic phases 
were dried over Na2SO4, filtered and then concentrated under reduced pressure.  The 
desired product was the minor product and therefore different conditions were utilized. 
 
1H NMR (400 MHz, (CDCl3) δ 7.96 (bs, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 8.0 
Hz, 1H), 7.19-7.08 (m, 2H), 5.66 (bs, 1H), 4.60 (d, J = 14 Hz, 1H), 3.88 (s, 3H), 3.15 (d, 
J = 17.2 Hz, 1H), 3.02-2.92 (m, 3H), 2.50 (dd, J = 14, 2.8 Hz, 1H), 2. 31 (d, J = 11.2 Hz, 
1H), 1.86 (s, 3H), 1.76-1.66 (m, 3H), 1.40 (s, 3H), 1.32 (s, 3H), 1.32-1.23 (m, 2H); 13C 
NMR (100 MHz, (CDCl3) δ 173.9, 172.7, 170.3, 139.8, 136.1, 126.8, 122.0, 119.8, 
117.9, 110.8, 101.8, 64.7, 60.0, 52.7, 40.9, 39.2, 37.5, 36.1, 33.4, 31.3, 30.9, 28.0, 24.6, 




















1H NMR, 400 MHz, CDCl3, filename: ms904p/PROTON_01 
 
 

















To a solution of bicyclo adduct 140 (7.7mg, 0.02 mmol) in THF (204 μL) at 0 °C was 
added 0.1 M HCl (204 μL) dropwise over 8 hours. The solution was then stirred at 0 °C 
for 2.5 hours. The mixture was then moved to the cold room (4 °C) and stirred for an 
additional 18 hrs. While still cold the solution was then quenched with a phosphate 
buffer (7.3 pH) and quickly extracted with Et2O. The combined organic phases were 
dried over Na2SO4, filtered and then concentrated under reduced pressure. The crude 






















To a solution of bicyclo adduct 139 (32.2mg, 0.087 mmol) in THF (0.879 mL) at 0 °C 
was added 0.1 M HCl (0.879 mL) dropwise over 4 hours. The mixture was then moved 
to the cold room (4 °C) and stirred for an additional 18 hrs. While still cold the solution 
was then quenched with a phosphate buffer (7.3 pH) and quickly extracted with Et2O. 
The combined organic phases were dried over Na2SO4, filtered and then concentrated 






















The crude amine 148 (275.2 mg, 0.696 mmol) was then dissolved in THF (6.9 mL) and 
cooled to -15 °C. To this was then added Ac2O (109 mL, 2.9 mmol) and subsequently 
the reaction was then slowly allowed to warm to 0 °C and stirred for 48 hours. The 
reaction mixture was quenched with NH4Cl and extracted with EtOAC. The combined 
organics were then dried over Na2SO4, filtered and then concentrated under reduced 
pressure. The crude pale yellow solid was purified via column chromatography 





















The crude amine 148 (0.879 mmol) was then dissolved in THF (0.879 mL) and cooled to 
0 °C. To this reaction mixture, was added Ac2O (24.9 μL, 0.263 mmol). The resulting 
solution was then moved to the cold room (4 °C) and stirred for 24 hours. The reaction 
mixture was quenched with NH4Cl and then extracted with EtOAC. The combined 
organics were then dried over Na2SO4, filtered, and then concentrated under reduced 
pressure.  The crude pale yellow solid was purified via column chromatography 

















dodecahydroquinolizino[2,3-b]carbazole-7a-carboxylic acid (161):  
 
 
To a stirred suspension of tellurium powder (0.355 mg) in dry degassed toluene (1.25 
mL), was added 2 M (Me3Al)2 (1.25 mL). The resulting solution was stirred at 112 °C for 
6 hours. The resulting 0.8 M solution of methyltellurolate (117 μL, 0.0937 mmol) was 
then added in one portion to a stirred solution of methylester (4.1 mg, 0.00937 mmol) in 
DCM (12.3 μL) at ambient temperature. The resulting orange solution was stirred for 6 
hours and then diluted with ethylacetate. The resulting solution was treated with 2 M 
solution of HCl and stirred for 2 hours. Aqueous was then separated from the organic 
phase and then extracted with EtOAc. The combine organic phases were then washed 
three times with brine, dried over Na2SO4, filtered and then concentrated under reduced 
pressure. The crude product was purified via column chromatography (MeOH/DCM 1/9) 
to accord a pale yellow solid (2.8 mg, 72%). 
 
Syn: 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.1 Hz, 1H), 7.26 (d, J = 8.1 Hz, 1H),  
7.05- 6.94 (m, 1H), 4.48 (d, J = 12.8 Hz, 1H), 3.08 (q, J = 16.8, 26.8 Hz, 2H), 2.95- 2.82 
(m, 2H), 2.61 (bs, 1H), 2.42 (q, J = 15.2, 24.4 Hz 2H),  1.91 (s, 3H), 1.74-1.62 (m, 3H), 
















120.6, 118.2, 117.2, 110.2, 100.5, 81.4, 66.4, 61.2, 60.3, 56.0, 41.2, 39.5, 36.9, 35.5, 











1H NMR, 400 MHz, CD3OD, filename: ms931p_proton 
 
















To acid (3 mg, 7.08x-6 mol) in toluene (83 μL), TEA (2.9 μL, 21.03x-6 mol) and DPPA 
(4.4 μL, 20.8x-6 mol) were added. The reaction was stirred at room temperature for 10 
minutes and then warmed to 100 °C for 16 hours. The reaction was then diluted with 
EtOAc and quenched with NH4Cl. The aqueous was separated from the organic and 
then extracted with EtOAc. The organics were combined, dried over Na2SO4, filtered, 
and then concentrated. The crude yellow product was purified using column 
chromatography (MeOH/DCM 1/19) to afford a white film (1.1 mg, 42%).  
 
1H NMR (400 MHz, CDCl3) δ 7.87 (bs, 1H) 7.41 (d, J = 8 Hz, 1H) 7.34 (d, J = 8 Hz, 1H) 
7.20-7.09 (m, 3H) 5.73 (bs, 1H) 4.75 (bs, 1H) 4.28-4.23 (m, 1H) 3.76- 3.64 (m, 1H) 
3.38-3.31 (m 1H) 3.20 (d, J = 16.8 Hz, 1H) 3.10 (dd, J = 14.4, 3.6 Hz, 1H) 2.56 (dd J = 
14.8, 3.6 Hz, 1H) 2.351-2.266 (m, 1H) 2.101-2.041 (m, 2H) 1.89 (s, 3H) 1.44 (s, 3H) 


































Ac2O (15.9 μL, 0.168 mmol) and formic acid (7.8 μL, 0.207 mmol) were stirred together 
at 50 °C for 2 hours. The solution was then cooled to -20 °C and then was added amine 
151 (25.6 mg, 0.649 mmol) in THF (20.4 μL). The resulting solution was then stirred for 
an additional 4 hours at -20 °C. The reaction was then concentrated under reduced 
pressure and then purified via column chromatography (MeOH/DCM 3/97) to afford a 
white solid.  
 
1H NMR (300 MHz, (CDCl3) δ 8.04 (bs, 1H), 7.95 (bs, 1H), 7.41-7.32 (m, 2H), 7.20 (m, 
2H), 7.19-7.08 (m, 2H), 5.80 (bs, 1H), 4.60 (d, J = 14 Hz, 1H), 3.90 (s, 3H), 3.23-3.17 
(m, 1H), 3.08-2.89 (m, 4H), 2.50 (dd, J = 14, 2.8 Hz, 1H), 2.31 (d, J = 11.2 Hz, 1H), 
1.84-1.67 (m, 4H), 1.47 (s, 3H), 1.34 (s, 3H). 
 
































To formaldehyde 176 (7.1 mg, 0.0167 mmol) cooled to 0 °C and was added BMS 
solution (20.9 μL, 0.0419 mmols). After stirring at an additional 10 minutes at 0 °C, the 
reaction was warmed to ambient temperature and stirred for an additional 10 hours. The 
reaction was then quenched with 50 μL of MeOH and stirred for 10 minutes followed by 
the slow addition of saturated NaHCO3. The reaction was then extracted with EtOAc 
and  combined organics were dried over Na2SO4, filtered, and then concentrated. The 
crude reaction was purified via preparatory thin layer chromatography (MeOH/DCM, 
2/98) to afford a white solid (4 mg, 61%).  
 
1H NMR (300 MHz, (CDCl3) δ 7.84 (bs, 1H), 7.95 (bs, 1H), 7.455 (d, J = 7.6 Hz, 1H) 
7.318 (d, J = 8 Hz, 1H), 7.17- 7.07 (m, 2H), 4.76 (d, J = 13.6 Hz, 1H), 3.82 (s, 3H), 3.67 
(d, J = 16.4 Hz, 1H), 2.75 (s, 1H), 2.61-2.54 (m, 3H), 2.32 (s, 3H), 2.27-2.23 (m, 1H), 

































pent-4-en-2-yl methanesulfonate (192):  
 
A solution of 4-penten-2-ol (1 g, 11.6 mmol) and CH3SO2Cl (1.16 mL, 15.09 mmol) in 10 
mL of DCM was cooled to -50 °C, and then TEA (2.42 mL, 17.4 mmol) was added 
dropwise. The solution was allowed to warm to 10 °C and after 5 min was re-cooled to 0 
°C. Cold water was then added, and the mixture was rapidly transferred to a separatory 
funnel using Et2O. The ether extract was washed with cold dilute HCl solution, NaHCO3 
solution, and saturated NaCl solution, and dried over MgSO4. After filtration, the 
solvents were removed using a rotary evaporator to give the crude mesylate as a pale 
brown oil. The mesylate was then purified by flash column chromatography (9:1 
Hexanes/Ethyl Acetate) to give a colorless oil (1.65 g, 86%).  
 
1H NMR (CDCl3, 300 MHz) δ 5.79 (m, 1H), 5.18 (m, 1H), 5.16 (m, 1H), 4.83 (m, 1H), 





















(R)-methyl 2-((tert-butoxycarbonyl)amino)-3-hydroxypropanoate (193):  
 
L-serine (20 g, 19.0 mmol) was refluxed in 250 mL of anhydrous methanol with AcCl 
(37.89 mL, 53.28 mmol) for 2 hours. The methanol was removed under reduced 
pressure. The residue was then dissolved in 633 mL of THF and added TEA (50.28 mL, 
36.01 mmol). The solution was then cooled to 0 °C and di-tert-butylcarbonate (37.05 g, 
16.97 mmol) in 282 mL of THF was added dropwise over 1 hour. The resulting solution 
was then warmed to room temperature and stirred overnight. The solvents were 
removed under reduced pressure and the residue was diluted with ether, and washed 
with NaHCO3. The aqueous layer was separated from the organic and then extracted 
three more times with ether. After drying over anhydrous MgSO4, the solvent was 
removed in vacuo and the product was purified by flash column chromatography 
(EtOAC/ hexanes 2:8) to give a clear oil (31.2g, 84% from L-ser).  
 
1H NMR (CDCl3, 300 MHz) δ 5.51 (bs, 1H), 4.34 (bs, 1H), 3.97-3.8 (m, 2H), 3.75 (s, 
























(R)-3-tert-butyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate (194): 
 
Ester 193 (18 g, 82.2 mmol) was dissolved in 303 mL of dry acetone. 
Dimethoxypropane (74.96 mL, 71.9 mmol) and boron trifluoride diethyl etherate (0.617 
mL, 5.0 mmol) were added sequentially. The reaction mixture was then stirred at room 
temperature for an additional 2.5 hours. The orange solution was then quenched with 
TEA (2 mL), stirred for an additional 15 minutes and then concentrated under reduced 
pressure. Saturated NaHCO3 was added to the residue and then solution was extracted 
three times with Et2O. The organic phases were combined, dried over NaSO4, filtered, 
and then concentrated reduced pressure. The resulting bright yellow oil was purified via 
flash column chromatography (EtOAC/Hexanes 1:9) to provide a pale yellow oil (18.8 g, 
88.8%).  
 
1H NMR (CDCl3, 300 MHz) δ 4.48 and 4.37 (bd, total 1H), 4.15-3.99 (m, 2H), 3.73 (s, 





























Garner Aldehyde (195): 
 
To a stirring solution of ester 194 (22.99 g, 88.66 mmol) in 185 mL of dry toluene at -78 
°C under an inert atmosphere, DIBAL-H (150 mL, 150 mmol) was added dropwise over 
1 hour.  The solution was then stirred an additional 2 hours at -78 °C, then was slowly 
warmed to -20 °C and quenched with 34.1 mL dry MeOH. Next, a saturated solution of 
Rochellʼs Salt (591 mL) was added and the reaction was stirred for an additional 2 
hours. The solids were filtered and washed with Et2O. The organic phase was 
separated from the aqueous, dried over magnesium sulfate, filtered, and concentrated 


















(S)-tert-butyl 2,2-dimethyl-4-vinyloxazolidine-3-carboxylate (196): 
 
To a solution of Ph3PCH3Br (18.32 g, 51.29 mmol) in 434 mL of THF at room 
temperature, KHMDS (98.4 mL, 49.2 mmol) was added dropwise. The solution was then 
stirred for an additional hour at room temperature. The resulting bright yellow solution 
was then cooled to -78 °C and a solution of garners aldehyde 195 (6.72 g, 29.3 mmol) in 
88 mL of THF was added dropwise. When the addition was complete, the solution was 
slowly warmed to room temperature and stirred for an additional 2 hours. The solution 
was added to 50 mL of dry MeOH and then poured into a 1:1 mixture of saturated 
Rochellʼs salt and water. The aqueous phase was then extracted with diethyl ether, 
dried over magnesium sulfate, filtered, and then concentrated. The product was purified 
via flash column chromatography (10% ethyl acetate/hexanes) to provide alkene as a 

















(S)-2-aminobut-3-en-1-ol hydrochloride (197): 
 
Protected oxazolidine 196 (3.70 g, 16.2 mmol) was stirred in 6 M HCl (12.0 mL) for 30 
minutes. The solution was then concentrated under reduced pressure. The white solid 
was further dried at 70 °C under a vacuum for 24 hours. The white solid (1.98, 98.4%) 















To HCl salt 197 (728.4 mg, 5.89 mmol) in DCM, was added TEA (1.79 mL, 12.08 
mmol), DMAP (72.84 mg, 0.1 wt%), and TBSCl (967 mg, 6.42 mmol), sequentially. The 
mixture was then stirred overnight at room temperature. The reaction was quenched 
with H2O for 10 minutes. The phases were separated, the organic phase was washed 
with brine, dried over Na2SO4, and filtered. The organic phase was then concentrated 
under reduced pressure to afford a clear oil (1.02 g, 86%) that was then taken on crude. 
 
1H NMR (CDCl3, 300 MHz) δ 5.85-5.74 (m, 1H), 5.21 (d, J = 17.4 Hz, 1H), 5.09 (d, J = 























To amine 198 (50 mg, 0.2482 mmol) in DCM at room temperature, was added TEA (38 
μL, 0.273 mmol) and then 2-nitrobenzenesulfonyl chloride (60.5 mg, 0.273 mmol. The 
solution was then stirred at room temperature overnight. Saturated NH4Cl was added 
and phases were separated. The aqueous phase was then extracted with DCM. The 
combined organic phases were washed with brine, dried over Na2SO4, filtered, and then 
concentrated under reduced pressure. The resulting brown oil was then purified via 
flash column chromatography (ETOAc/hexanes 2:8) to afford a pale yellow oil (92.9 mg, 
96%).  
1H NMR (CDCl3, 300 MHz) δ 8.10-8.05 (m, 1H), 7.88-7.83 (m, 1H), 7.73-7.67 (m, 2H), 
5.92 (d, J = 7.2 Hz, 1H), 5.75-5.64 (m, 1H), 5.15 (d, J = 17.1 Hz, 1H), 5.04 (d, J = 10.5 
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Appendix 1: Research Proposal 
 
 
Total Synthesis of Marthiapeptide A, an Anti-infective and Cytotoxic Polythiazole 





The aim of this proposal is to develop a convergent synthetic plan for the total synthesis 
Marthiapeptide A1 (1, Figure 4) utilizing synthetic methods that are accessible to 
undergraduate researchers. Marthiapeptide A, a cyclopeptide isolated from sea 
sediment off the southern China coast, has shown antibacterial activity and strong 
cytotoxic activity making it an interesting prospect for potential therapeutics. It exhibited 
MIC values ranging from 2.0 to 8.0 μg/mL, and IC50 values ranging from 0.38 to 0.52 
μM.1 The unique trithiazole-thiazoline moiety make Marthapeptide A an ideal lead 
compound for drug discovery. Discussed herein will be the synthetic design of  
Marthiapeptide A and other potential antibacterial and cytotoxic therapeutics. 
 
Figure 4: Natural Product Marthapeptide A.  



















1. To Develop a convergent synthetic plan for the total synthesis Marthiapeptide A 
(1, Figure 4). 
2. To confirm the correct structure of Marthiapeptide A. 
3. To synthesize multiple analogs by systematically changing the amino acid 
framework of Marthiapeptide A.  
4. To conduct initial structure-activity relationship (SAR) analysis on these analogs. 
 Background and Significance: 
Antimicrobial Resistance is an emerging problem in modern medicine. Drug 
resistant organisms are extending hospital stays and increasing mortality rates all over 
the world. The discovery and development of new antibiotics is necessary for effective 
treatment of these drug resistant super bugs.2 In the United States cancer is the second 
most common cause of death among adults. The discovery and development of novel 
cancer therapeutics could help half a million Americans each year alone.3 Therefore, 
there is a critical unmet need to develop new antibiotics and cancer therapeutics.  
 
Figure 5: Members of the cyclic polyazole family of natural products. 
Marthapeptide A belongs to a new and emerging family of natural products that 
contain four or more sequential 2,4-disubstituted oxazoles/oxazolines and 




















































































Mechercharmycin A5 (3), YM-2163916,7 (4), and Urukthapelstatin A8 (5) (Figure 5). 
Members of this cyclic polyazole family of natural products show a diverse array of 
biological activities. While Telomestatin is a known Telemersase inhibitor,9,10 the 
specific mode of action for the other members in this family remains unknown. 
Furthermore, understanding how Marthapeptide A acts in the cell, may also shed light 
what gives the other members of this family its cytotoxic properties. A deeper 
understanding about the SAR has the potential to identify new antibacterial and 
cytotoxic therapeutics. The unique trithiazole-thiazoline moiety make Marthapeptide A 
an ideal lead compound for drug discovery. In order to conduct preliminary SAR studies, 
first  the total synthesis must be completed and the proposed structure must be verified. 
To date no total synthesizes have been reported.  
Previous macrocyclizations: 
The design and synthesis of cyclic polyazole natural products has been subject 
to study over the last decade. The synthesizes of Telomestatin11 (2), Mechercharmycin 
A12 (3), YM-21639113,14 (4), and Urukthapelstatin A15 (5) have all been reported. 
Macrocyclization has been a synthetic challenge for members of this family.16,17 It has 
been hypothesized, the problem arises due to the rigidity of the consecutive heterocycle 
backbone.17 To overcome this synthetic challenge macrocyclization must be completed 
prior to the formation of the rigid heterocyclic backbone. As shown in Scheme 56, in the 
total synthesis of Urkthapelstatin A15(5), macrocyclization was achieved by treatment of 
intermediate 6 with 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxid hexafluorophosphate (HATU), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-
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methylmorpholinium chloride (DMTMM) , 2,4,6-tripropyl-1,3,5,2,4,6-
trioxatriphosphorinane-2,4,6-trioxide (T3P), and N,N-diisopropylethylamine (DIPEA). 
The resulting macrolide (7) was then converted to Urkthapelstatin A (5) as 2:1 mixture of 
E/Z inseparable isomers by a two step oxazole formation.   
 
Scheme 56: The macrocyclic formation of Urukthapelstatin A. 
 In the synthesis YM-21639114, the macrocyclization shown in Scheme 57, is 
achieved by treatment of intermedia 8 with HATU and 4-methylmorpholine (NMM) in 
dicloromethane (DCM) and dimethylformamide (DMF). The thioazole unit was then 
constructed by treatment of thioamide 9 with (diethylamino)sulfur trifluoride (DAST) and 
then manganese (IV) oxide (Mn2O).  
 
Scheme 57: The macrocyclic formation of YM-216391. 
In same way also, Alvarez and coworkers12 first form the macrocycle and then 
subsequently form the thiazole moiety in their synthesis Mechercharmycin A (Scheme 












































































































































and bromoketone. Then resulting the bromoketone is then condensed on to the 
thioamide by refluxing in ethanol to afforded thiazole 11. The free alcohol was then 
converted to mesylate and eliminated to afford Mechercharmycin (3).  
 
 
Scheme 58: The macrocyclic formation of Merchercharmycin A. 
Previous SAR studies: 
While little is known about the specific mode of action that renders this family of 
natural products of cytotoxic, some initial SAR studies have been conducted. These 
previous studies can be used to gain valuable insight which we can apply to our own 
SAR analysis of Marthapeptide A. During these studies, key structural features have 
been identified to directly correlate to biological activity. We plan on implementing and 
incorporating these key structural features when we synthesize our own library of 
compounds.   
Perhaps the most important structural feature pertains to rigidity of the 
macrocycles. When the ring open conformers were submitted for biological testing there 
was a sharp decrease in cytotoxic activities. 5,12 . Mechercharmycin B (12) and the ring 
open analog 13, shown in Figure 6, are two such examples. It has then been reasoned 
that the biological activity arises from the macrocycles rigid conformation. Therefore the 









































































Figure 6: Examples of biologically inactive conformers. 
Also, it should be noted that substituting the thiazole moiety for the oxazole 
moiety (14) in the Mechercharmycin A framework results in loss of biological activity18 
(Figure 7). Thus suggesting that the thiazole moiety is key for cytotoxic activity. Since 
Marthiapeptide A contains three thiazole rings, it may be possible to systematically 
exchange each for an oxazole and determine if the location if the thiazole ring is 
important for biological activity. Also, converting the thiazoline moiety to a thiazole would 
result in a sequential tetrathiazole analog, which could possibly lead to increased 
biological activity.    
 
Figure 7: Penta-oxazole analog of Mechercharmycin A. 
Research and Design Methods:  
We believe we can access Marthiapeptide A (1) via a coupling of Fragment A 





























































































natural products must prior to the formation of the rigid heterocyclic backbone. 
Therefore, after the initial coupling and macrocyclization we will install the thiazole 
moiety.  
 
Scheme 59: Retrosynthetic analysis of Marthiapeptide A. 
Synthesis of Fragment A 
We envision the synthesis of Fragment A, shown in Scheme 60, starting with 
commercially available Boc-L-alanine (17). The acid will be converted to the methyl 
ester by treatment with trimethylsilsydiazomethane (TMSD). The resulting ester will then 
be converted to the amide by stirring in ammonium hydroxide and methanol. Finally, 
thioamide 18 can be accessed by treatment with Lawessonʼs reagent. Condensation of 
the thioamide 18 with ethyl bromopyruvate in the presence of calcium carbonate and 
ethanol will provide thiazole 19. Treatment of thiazole 19 with ammonium hydroxide in 
methanol and then Lawessonʼs reagent sequentially with provide us with thioamide 20. 
The resulting thioamide will then be condensed with ethyl bromopyruvate to afford 
dithiazole 21. These steps can then be repeated again to provide first thioamide 22 and 
then trithiazole ester 23. The resulting ester will then be stirred with lithium hydroxide 









































Scheme 60: Proposed synthesis of Fragment A. 
Synthesis of Fragment B 
The synthesis of Fragment B will start by coupling Boc-D-phenylalanine 24, with L-
isoleucine methyl ester 25 using dicyclohexylcarbodiimide (DCC) and 4-
(dimethylamino)pyridine (DMAP). The resulting dipeptide 26 will then be deprotected 
using trifluoroacetic anhydride (TFAA) in DCM to afford free amine 27. This amine will 
then be coupled with cysteine derivative 28 yielding substrate 29. The protected amine 























































































Scheme 61: Proposed synthesis of Fragment B. 
Macrocyclization: 
To complete the synthesis Fragment A (15) and Fragment B (16) will then be 
coupled together providing us with peptide 30. Subsequent deprotection of both the Boc 
group and the ester will provide us with the desired macrocyclic precursor 31. The 
macrocyclization will be carried out using DPPA, HOBt, DMAP and DIPEA. With 
macrolide 32 in-hand we plan on installing the thiazoline moiety using Kellyʼs19 method. 
Deprotection and the cyclocondensation will be achieved by treatment with Ph3P(O)-Tf2-
anisole in DCM to furnish us with Marthiapeptide A. With Marthiapeptide A in hand we 


























































Scheme 62: Proposed late stage synthesis of Marthapeptide A. 
Synthesis of Analogs 
 A number of different analogs can be readily accessed following our convergent 
synthesis of Marthiapeptide A.  Each one of these analogs will be synthesized in 10-20 
mg quantities and will be used in our initial SAR studies. Or goal is to synthesize a large 
number of candidates for biological testing in the next 3 years. Analogs that will be 
submitted for testing include the enantiomer (33) and diastereomers (34-37) of 
Marthiapeptide A. We do not plan on testing any of the open chain intermediates since 
they have been reported to have diminished biologically active.   
Comparing the peptide framework of Marthiapeptide A with the other members of 
the family, allows us to envision other possible analogs. Both Mechercharmycin A (3), 
YM-216391 (4) contain L-valine moieties that are not present in Marthiapeptide A.  To 














































































































Marthiapeptide A backbone and that contain L-valine in the place of the L-alaine moiety 
(38).   
It has already been shown that the thiazole moiety is important for biological 
activity; However no studies have been conducted to determine the importance of the 
thiazoline ring system. Thus we plan on synthesizing an analog that contains 
concatenated tetrathiazole ring system (39). This analog can be easily be synthesized 
from a one step oxidation of the Marthiapeptide A. 20,21 
 
Figure 8: Some of the analogs for initial SAR studies. 
Potential Limitations and Difficulties: 
Difficulties, anticipated and not, are always part of every research program. Below are 
listed the anticipated difficulties and how we plan to overcome said difficulties should 
they arise.  
1. It is possible that proposed structure of Marthiapeptide A is not correct. If this is 


























































































































(36) (37) (38) (39)
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the spectrometric data. Using these discrepancies we should be able to 
determine if there is an incorrect assignment of one or more stereogenic centers.  
2. It is possible that the proposed macrocyclization will be unsuccessful. If this is the 
case, there are a number of different coupling reagents and conditions that will 
be investigated. Also if all these conditions fail we can redesign the retro 
synthetic plan allowing for the macrocyclization at another place in the molecule. 
3. It is possible that the different analogs synthesized may not lead to increased 
potency and biological activity. If this is the case we will investigate analogs that 
also differ substantially from the Marthiapeptide A. We will introduce different 
heterocycles in place of the trithiazole ring system and we will investigate 
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List of Abbreviations  
 
Ac     acetyl 
Ac2O     acetic anhydride 
AcOH     acetic acid 
AIBN     2,2-azo bisisobutyronitrile 
BBN (9-BBN)   9-borabicyclo[3.3.1]nonane  
Bn     benzyl 
Boc     tert-butoxycarbonyl 
Boc2O     di-tert-butyl dicarbonate 




BMS borane dimethylsulfide 
Cbz benzyloxycarbonyl 
CoA co-enzyme A 
Collidine 2,4,6-trimethylpyridine 
18-crown-6 1,4,7,10,13,16-hexaoxacyclooctadecane 






DBU     1,8-diazabicycol[5.4.0]undec-7-ene 
DCB 1,4-dicyanobenzene  
DCM dichloromethane 
DCC dicyclohexylcarbodimide 
DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone  
DEAD diethyl azocarboxylate 








DPPA diphenylphosphoryl azide  
2,6-DTBP 2,6-di-tert-butylpyridine 




EtOAc ethyl acetate 







H3R histamine 3 receptor 
Im imidazole 
IMDA intermolecular Diels-Alder  
IPP isopenylpyrophosphate 
KF potassium fluoride 
KHMDS potassium (bis)trimethylsilyl amide 
Ki inhibitor constant 
LAH lithium aluminum hydride 
LDA lithium diisopropylamine 
LHMDS (or LiHMDS) lithium (bis)trimethylsilyl amide 
LiOH lithium hydroxide 
2,6-lutidine 2,6-dimethylpyridine 
mCPBA    meta-chloroperbenzoic acid 
Me methyl 
MeCN acetonitrile 
MeI methyl iodide 
MeOH methanol 
MgCl2 magnesium chloride 
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Ms methanesulfonyl (mesylate) 
MsCl methanesulfonyl chloride 
NaCNBH4 sodium cyanoborohydride 
NBS N-bromosuccinimide 
NCS N-chlorosuccinimde 
NHMDS (or NaHMDS) sodium (bis)trimethylsilyl amide 
NMM N-methyl morpholine 
Phen phenanthrene 
PMB p-methoxybenzyl 
PPTS pyridinium p-toluenesulfonate 
PTLC preparative thin layer chromatography 
i-Pr isopropyl 
Py. or Pyr pyridine 
Red-Al sodium bis(2-methoxyethoxy)-aluminum hydride  
TBAF tetrabutylammonium fluoride 
TBDPS tert-butyldiphenylsilyl 
TBS tert-butyldimethylsilyl 
TBSCl tert-butyldimethylsilyl chloride 
t-DDSH tert-dodecanethiol  
t-BuOK potassium tert-butoxide 
TEA triethylamine 
TFA trifluoroacetic acid 
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TFAA trifluoroacetic anhydride 
TfN3 trifluoromethanesulfonyl azide 
Tf3O trifluoromethanesulfonic anhydride 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMS trimethylsilyl 
TMSI trimethylsilyl iodide 
TMSCl trimethylsilyl chloride 
  
 
 
 
